<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAB</journal-id>
<journal-id journal-id-type="hwp">sptab</journal-id>
<journal-title>Therapeutic Advances in Musculoskeletal Disease</journal-title>
<issn pub-type="ppub">1759-720X</issn>
<issn pub-type="epub">1759-7218</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1759720X13485503</article-id>
<article-id pub-id-type="publisher-id">10.1177_1759720X13485503</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Biomarkers in systemic lupus erythematosus: challenges and prospects for the future</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Liu</surname><given-names>Chau-Ching</given-names></name>
<aff id="aff1-1759720X13485503">Allegheny Singer Research Institute,Temple University School of Medicine,320 East North Avenue Pittsburgh, PA 15212, USA</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Kao</surname><given-names>Amy H.</given-names></name>
<aff id="aff2-1759720X13485503">The Lupus Center of Excellence, Department of Medicine, Allegheny Singer Research Institute, West Penn Allegheny Health System and Temple University School of Medicine, Pittsburgh, PA, USA</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Manzi</surname><given-names>Susan</given-names></name>
<aff id="aff3-1759720X13485503">The Lupus Center of Excellence, Department of Medicine, Allegheny Singer Research Institute, West Penn Allegheny Health System and Temple University School of Medicine, Pittsburgh, PA, USA</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Ahearn</surname><given-names>Joseph M.</given-names></name>
<aff id="aff4-1759720X13485503">The Lupus Center of Excellence, Department of Medicine, Allegheny Singer Research Institute, West Penn Allegheny Health System and Temple University School of Medicine, Pittsburgh, PA, USA</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-1759720X13485503"><email>cliu@wpahs.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>5</volume>
<issue>4</issue>
<fpage>210</fpage>
<lpage>233</lpage>
<permissions>
<copyright-statement>© The Author(s), 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The search for lupus biomarkers to diagnose, monitor, stratify, and predict individual response to therapy is currently more intense than ever before. This effort is essential for several reasons. First, epidemic overdiagnosis and underdiagnosis of lupus, even by certified rheumatologists, leads to errors in therapy with concomitant side effects which may be more serious than the disease itself. Second, identification of lupus flares remains as much an art as it is a science. Third, the capacity to stratify patients so as to predict those who will develop specific patterns of organ involvement is not currently possible but would potentially lead to preventive therapeutic strategies. Fourth, only one new drug for the treatment of lupus has been approved by the US Food and Drug Administration in over 50 years. A major obstacle in this pipeline is the dearth of biomarkers available to prove a patient has responded to an experimental therapeutic intervention. This review will summarize the challenges faced in the discovery and validation of lupus biomarkers, the most promising lupus biomarkers identified to date, and the promise of future directions.</p>
</abstract>
<kwd-group>
<kwd>biomarker</kwd>
<kwd>lupus</kwd>
<kwd>systemic lupus erythematosus</kwd>
<kwd>SLE</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1759720X13485503" sec-type="intro">
<title>Introduction</title>
<p>Systemic lupus erythematosus (SLE) is arguably the most serologically and clinically diverse autoimmune disease, with immunopathogenic abnormalities continuously being uncovered and clinical manifestations widely varying in individual patients. Immune dysregulation leads to excess production of autoantibodies and immune complexes, excess complement activation, and insidious tissue inflammation in patients with SLE, which together cause a clinical syndrome with multi-organ involvement and hard-to-predict courses [<xref ref-type="bibr" rid="bibr35-1759720X13485503">Crispin <italic>et al.</italic> 2010b</xref>; <xref ref-type="bibr" rid="bibr140-1759720X13485503">Rahman and Isenberg, 2008</xref>; <xref ref-type="bibr" rid="bibr172-1759720X13485503">Tsokos, 2011</xref>]. Owing to its complex nature, SLE remains one of the greatest challenges to both investigators and physicians.</p>
<p>Over the past several decades, tremendous enthusiasm and efforts have been devoted to tackling the numerous challenges ranging from understanding the etiopathogenesis of SLE, through the development of diagnostic tests and biomarkers, to improved care for patients with SLE. Although significant progress has been made, there are still many unmet needs in lupus research and patient care. Fundamental to the unmet needs is the lack of reliable lupus biomarkers for diagnosis, monitoring, stratification, and prediction of response to therapy.</p>
<p>Based on scientific and clinical rationale, a biomarker is defined as a measurement, including but not limited to a genetic, biological, biochemical, molecular, or imaging event whose alterations correlate with the pathogenesis and/or manifestations of a disease and can be evaluated qualitatively and/or quantitatively in laboratories [<xref ref-type="bibr" rid="bibr74-1759720X13485503">Illei <italic>et al.</italic> 2004a</xref>, <xref ref-type="bibr" rid="bibr75-1759720X13485503">2004b</xref>]. Given the rapid advance in the understanding of SLE pathogenesis and development of new technologies, an impressive spectrum of SLE biomarkers has been accrued during the past few years. A comprehensive review of these biomarkers will be beyond the scope of this article; readers can reference several recently published reviews [<xref ref-type="bibr" rid="bibr2-1759720X13485503">Ahearn <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr64-1759720X13485503">Herbst <italic>et al.</italic> 2012</xref>]. Instead, this report will focus on select groups of potential biomarkers that have been developed based on or in response to: (1) recent understanding of SLE pathogenesis (e.g. epigenetics, cytokines) or cutting-edge technologies (e.g. proteomics); (2) clinical importance in SLE management (e.g. lupus nephritis); and (3) emerging appreciation of the need of composite panels, rather than individual lupus biomarkers. Finally, we will discuss the current limitations and future directions for discovery and validation of lupus biomarkers.</p>
</sec>
<sec id="section2-1759720X13485503">
<title>Biomarkers originated from better understanding of SLE pathogenesis</title>
<p>The pathogenesis of SLE is multifactorial and multistaged, with various genetic, epigenetic, environmental, gender, and immunoregulatory factors contributing to the susceptibility, onset, progress, and prognosis of the clinical disease in a given patient [<xref ref-type="bibr" rid="bibr35-1759720X13485503">Crispin <italic>et al.</italic> 2010b</xref>; <xref ref-type="bibr" rid="bibr104-1759720X13485503">Manderson <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr117-1759720X13485503">Mok and Lau, 2003</xref>; <xref ref-type="bibr" rid="bibr121-1759720X13485503">Moser <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr153-1759720X13485503">Sarzi-Puttini <italic>et al.</italic> 2005</xref>]. Genetic factors clearly confer susceptibility of an individual to the development of SLE. In rare cases, the development of SLE is due to the deficiency of a single gene product (e.g. complement C1q) [<xref ref-type="bibr" rid="bibr137-1759720X13485503">Pickering <italic>et al.</italic> 2000</xref>]. Much more commonly, variations (single nucleotide polymorphisms, gene copy numbers, etc.) at multiple genetic loci are believed to increase the risk of SLE in a hierarchical interactive manner [<xref ref-type="bibr" rid="bibr121-1759720X13485503">Moser <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr125-1759720X13485503">Nath <italic>et al.</italic> 2004</xref>]. Although extensive studies have associated many common genetic variants with SLE [<xref ref-type="bibr" rid="bibr47-1759720X13485503">Deng and Tsao, 2010</xref>; <xref ref-type="bibr" rid="bibr55-1759720X13485503">Flesher <italic>et al.</italic> 2010</xref>], the cumulative effect size of the loci identified so far accounts for only 15–20% of the heritability of SLE [<xref ref-type="bibr" rid="bibr105-1759720X13485503">Manolio <italic>et al.</italic> 2009</xref>]. The variations potentially underlying the remaining 75–80% of the heritability appear to be missing.</p>
<sec id="section3-1759720X13485503">
<title>Epigenetics-related biomarkers</title>
<p>The ‘missing heritability’ has led to a renewed appreciation of epigenetic factors. Because SLE affects predominantly women of child-bearing age, it is widely accepted that female hormones contribute to the development of SLE through mechanisms that are not fully elucidated [<xref ref-type="bibr" rid="bibr180-1759720X13485503">Weckerle and Niewold, 2011</xref>]. However, epigenetically dysregulated expression of genes located on chromosome X, e.g., the CD40 Ligand (CD40L) gene, may also contribute to the female prevalence of SLE [<xref ref-type="bibr" rid="bibr101-1759720X13485503">Lu <italic>et al.</italic> 2007</xref>].</p>
<p>Epigenetics refers to heritable modifications that regulate gene expression without alterations in DNA sequence [<xref ref-type="bibr" rid="bibr19-1759720X13485503">Bird, 2007</xref>]. Epigenetic effects, which are heritable (but specific to different cells), stable (but reversible), and subject to environmental influences, may account for several perplexing observations such as the incomplete concordance of SLE in monozygotic twins [<xref ref-type="bibr" rid="bibr71-1759720X13485503">Hughes and Sawalha, 2011</xref>; <xref ref-type="bibr" rid="bibr76-1759720X13485503">Javierre <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr78-1759720X13485503">Jeffries and Sawalha, 2011</xref>; <xref ref-type="bibr" rid="bibr158-1759720X13485503">Shen <italic>et al.</italic> 2012</xref>]. Common epigenetic mechanisms, including DNA methylation, histone modifications, and microRNA-mediated regulation, play important roles in modulating gene expression over the cell cycle, lineage commitment, and cellular function throughout the body [<xref ref-type="bibr" rid="bibr56-1759720X13485503">Fraga <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr94-1759720X13485503">Laurent <italic>et al.</italic> 2010</xref>]. The immune system, naturally, is also under tight control at the epigenetic level [<xref ref-type="bibr" rid="bibr4-1759720X13485503">Allan <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr40-1759720X13485503">Dai and Ahmed, 2011</xref>; <xref ref-type="bibr" rid="bibr54-1759720X13485503">Fields <italic>et al.</italic> 2002</xref>; <xref ref-type="bibr" rid="bibr72-1759720X13485503">Hughes <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr141-1759720X13485503">Rauch <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr142-1759720X13485503">Renaudineau and Youinou, 2011</xref>]. Therefore, aberrant epigenetic regulation may contribute to the complex array of immune abnormalities and influence the disease manifestations in lupus patients (<xref ref-type="table" rid="table1-1759720X13485503">Table 1</xref>).</p>
<table-wrap id="table1-1759720X13485503" position="float">
<label>Table 1.</label>
<caption>
<p>Epigenetic alterations and potential epigenetic biomarkers identified in SLE.</p>
</caption>
<graphic alternate-form-of="table1-1759720X13485503" xlink:href="10.1177_1759720X13485503-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Mechanism</th>
<th align="left">Target</th>
<th align="left">Cell Type</th>
<th align="left">Alteration</th>
<th align="left">Consequence</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="8" valign="top">DNA methylation</td>
<td>ITGAL (CD11a)</td>
<td>CD4 T cells</td>
<td>Hypomethylation</td>
<td>Increased CD11a expression</td>
</tr>
<tr>
<td>CD70 (TNFSF7)</td>
<td>CD4 T cells</td>
<td>Hypomethylation</td>
<td>Increased CD70 expression and B-cell costimulation</td>
</tr>
<tr>
<td>CD154 (CD40L)</td>
<td>CD4 T cells</td>
<td>Hypomethylation</td>
<td>Increased B-cell costimulation</td>
</tr>
<tr>
<td>Perforin</td>
<td>CD4 T cells</td>
<td>Hypomethylation</td>
<td>Increased perforin expression</td>
</tr>
<tr>
<td>KIR family</td>
<td>CD4 T cells</td>
<td>Hypomethylation</td>
<td>Increased KIR expression</td>
</tr>
<tr>
<td>RUNX3</td>
<td>CD4 T cells</td>
<td>Hypermethylation</td>
<td>Dysregulation of ITGAL (CD11a) expression</td>
</tr>
<tr>
<td>MMP9</td>
<td>CD4 T cells</td>
<td>Hypomethylation</td>
<td>Cellular basement membrane breakdown</td>
</tr>
<tr>
<td>CD9</td>
<td>CD4 T cells</td>
<td>Hypomethylation</td>
<td>T-cell activation</td>
</tr>
<tr>
<td>Histone modification</td>
<td>Histone H4</td>
<td>Monocytes</td>
<td>Increased acetylation</td>
<td>Increased expression of proinflammatory cytokines</td>
</tr>
<tr>
<td rowspan="5" valign="top">MicroRNA</td>
<td>miR-146a</td>
<td>PBMCs</td>
<td>Underexpression</td>
<td>Type I IFN overproduction</td>
</tr>
<tr>
<td>miR-21</td>
<td>CD4 T cells</td>
<td>Overexpression</td>
<td>Downregulation of DNMT1 (indirect) and thus decreased DNA methylation</td>
</tr>
<tr>
<td>miR-148a</td>
<td>CD4 T cells</td>
<td>Overexpression</td>
<td>Downregulation of DNMT1 (direct) and decreased DNA methylation</td>
</tr>
<tr>
<td>miR-125a</td>
<td>PBMCs</td>
<td>Underexpresssion</td>
<td>Increased KLF expression and thus RANTES overproduction</td>
</tr>
<tr>
<td>miR-126</td>
<td>CD4 T cells</td>
<td>overexpression</td>
<td>Downregulation of DNMT1 and decreased DNA methylation</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1759720X13485503">
<p>IFN, interferon; KIR, killer immunoglobulin-like receptor; KLF, Kruppel-like factor; MMP, matrix metalloproteinase PBMC, peripheral blood mononuclear cell; RANTES, regulated on activation normal T cell expression and secreted; RUNX, runt-related transcription factor; SLE, systemic lupus erythematosus</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section4-1759720X13485503">
<title>DNA methylation</title>
<p>The expression of a gene is initiated by the access of transcription factors to the specific DNA region. Methylation of the promoter and cytosine-P-guanosine (CpG)-rich regions (CpG islands) of genomic DNA by DNA methyl transferases (DNMTs) prevents the binding of transcription factors and is an important negative regulator of gene expression. Decreased methylation (hypomethylation) of DNA will lead to aberrant gene expression. Global DNA hypomethylation in CD4 T cells has long been observed in SLE, initially in drug-induced SLE and later in idiopathic SLE [<xref ref-type="bibr" rid="bibr33-1759720X13485503">Cornacchia <italic>et al.</italic> 1988</xref>; <xref ref-type="bibr" rid="bibr72-1759720X13485503">Hughes <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr143-1759720X13485503">Richardson <italic>et al.</italic> 1990</xref>]. It is now known that hydralazine and procainamide inhibit DNA methylation and thus may induce SLE in some individuals [<xref ref-type="bibr" rid="bibr33-1759720X13485503">Cornacchia <italic>et al.</italic> 1988</xref>]. Hypomethylation of the regulatory regions of several genes known to be involved in the pathogenesis of SLE, such as CD70 (a costimulatory molecule), CD40L (CD154; also a costimulatory molecule), ITGAL [CD11a; a subunit of lymphocyte function-associated antigen 1 (LFA-1)], perforin (a cytolytic protein), killer immunoglobulin-like receptors (KIRs), interleukin (IL)-10, and IL-13 have been reported [<xref ref-type="bibr" rid="bibr11-1759720X13485503">Basu <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr85-1759720X13485503">Kaplan <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr98-1759720X13485503">Liu <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr99-1759720X13485503">Lu <italic>et al.</italic> 2002</xref>, <xref ref-type="bibr" rid="bibr100-1759720X13485503">2005</xref>, <xref ref-type="bibr" rid="bibr101-1759720X13485503">2007</xref>; <xref ref-type="bibr" rid="bibr130-1759720X13485503">Oelke <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr196-1759720X13485503">Zhao <italic>et al.</italic> 2010a</xref>]. Consequently, DNA hypomethylation may cause increased cytokine production and hyperactivity of CD4 T cells and increased immunoglobulin production by B cells. The degree of reduced DNA methylation and overexpression of proteins encoded by the hypomethylated genes in SLE T cells have been reported to correlate with disease activity [<xref ref-type="bibr" rid="bibr99-1759720X13485503">Lu <italic>et al.</italic> 2002</xref>].</p>
<p>It has been a puzzle that monozygotic twins are at increased risk to develop SLE but the concordance rate has never reached 100% [<xref ref-type="bibr" rid="bibr45-1759720X13485503">Deapen <italic>et al.</italic> 1992</xref>]. A recent genome-wide DNA methylation study showed significant epigenetic variation in leukocytes derived from disease-discordant monozygotic twins; specifically differential methylation of 49 autoimmunity-relevant genes in the white blood cell population between the affected twins and their healthy monozygotic siblings were identified [<xref ref-type="bibr" rid="bibr76-1759720X13485503">Javierre <italic>et al.</italic> 2010</xref>]. This study lends support to the possibility that variations in epigenetic modifications may drive the difference in SLE development during the life course of monozygotic twins. Jeffries and colleagues recently conducted a case-control study utilizing high-throughput methylation arrays to scan 27,578 CpG sites in the promoter region of 14,495 genes [<xref ref-type="bibr" rid="bibr77-1759720X13485503">Jeffries <italic>et al.</italic> 2011</xref>]. They identified 236 hypomethylated sites (representing 232 genes) and 105 hypermethylated sites (representing 104 genes) in CD4 T cells of SLE patients. A more recent genome-wide study reported that the methylation status of the IL-10 and IL-1R2 genes was significantly reduced in SLE patient samples compared to healthy control samples. Moreover, the SLE patients with hypomethylated IL-10 and IL-1R2 genes appeared to have higher disease activity [<xref ref-type="bibr" rid="bibr96-1759720X13485503">Lin <italic>et al.</italic> 2012</xref>]. These studies, taken together, suggest that genome-wide DNA methylation studies may aid in identifying potential biomarkers that may correlate with the pathogenic process and/or disease activity of SLE.</p>
</sec>
<sec id="section5-1759720X13485503">
<title>Histone modifications</title>
<p>Histone proteins are the major component of nucleosomes (the basic subunit of chromatin) and help determine which part of the chromatin is accessible for active transcription [<xref ref-type="bibr" rid="bibr102-1759720X13485503">Luger <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr181-1759720X13485503">Williamson and Pinto, 2012</xref>]. Covalent modification of histone proteins may alter chromatin structure (but not the DNA sequence) and, hence, regulate gene expression at the epigenetic level. For example, acetylation and methylation of a specific lysine residue (lysine 9) on histone 3 (H3K9) have been shown to enhance or repress gene transcription, respectively [<xref ref-type="bibr" rid="bibr145-1759720X13485503">Roh <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr160-1759720X13485503">Snowden <italic>et al.</italic> 2002</xref>; <xref ref-type="bibr" rid="bibr182-1759720X13485503">Wilson <italic>et al.</italic> 2009</xref>]. Reduced global levels of methylated H3K9 and H3 acetylation have been reported in CD4 T cells of SLE patients [<xref ref-type="bibr" rid="bibr70-1759720X13485503">Hu <italic>et al.</italic> 2008</xref>]. In addition, hyperacetylation of histone 4 (H4) and overexpression of several genes have been reported in monocytes of SLE patients [<xref ref-type="bibr" rid="bibr195-1759720X13485503">Zhang <italic>et al.</italic> 2010</xref>]. These findings point to widespread variations in histone modifications in immune cells of SLE patients and such changes may serve as potential biomarkers for elucidating the pathogenesis of SLE.</p>
</sec>
<sec id="section6-1759720X13485503">
<title>MicroRNAs</title>
<p>MicroRNAs (miRNAs or miR) are recently discovered, short (20–24 base pairs in length), noncoding ribonucleic acids (RNAs) that play important roles in the regulation of gene expression post-transcriptionally [<xref ref-type="bibr" rid="bibr10-1759720X13485503">Bartel, 2004</xref>; <xref ref-type="bibr" rid="bibr25-1759720X13485503">Carthew and Sontheimer, 2009</xref>; <xref ref-type="bibr" rid="bibr52-1759720X13485503">Fabian <italic>et al.</italic> 2010</xref>]. miRNAs bind to homologous sequences present in messenger RNA (mRNA) transcripts, and regulate gene expression by directly cleaving the target mRNA or effectively blocking the subsequent translation of the target mRNA. The miRNA-mediated regulatory network is extremely complex: a single miRNA may regulate hundreds to over thousands of mRNAs, and a single mRNA may be targeted by multiple miRNA. The production of miRNAs themselves is also under tight genetic as well as epigenetic regulations.</p>
<p>During the last several years, accumulating evidence has indicated that miRNAs are critical not only for the development of the immune system, but also for regulation of adaptive and innate immune responses [<xref ref-type="bibr" rid="bibr9-1759720X13485503">Baltimore <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr186-1759720X13485503">Xiao and Rajewsky, 2009</xref>]. Therefore, not surprisingly, abnormalities in the expression and functioning of miRNAs have been identified as part of the pathogenesis of autoimmune diseases including SLE [<xref ref-type="bibr" rid="bibr40-1759720X13485503">Dai and Ahmed, 2011</xref>; <xref ref-type="bibr" rid="bibr158-1759720X13485503">Shen <italic>et al.</italic> 2012</xref>] . Dai and colleagues first reported the identification of six miRNAs whose expression was altered in the peripheral blood mononuclear cells (PBMCs) prepared from patients with SLE, but not patients with idiopathic thrombocytopenic purpura [<xref ref-type="bibr" rid="bibr41-1759720X13485503">Dai <italic>et al.</italic> 2007</xref>]. Since then, several investigators have conducted and reported studies aimed at detecting and profiling miRNA expression in blood cells (PBMCs, T cells, etc), body fluid (serum, plasma, urine, etc.), and tissues taken from patients with SLE [<xref ref-type="bibr" rid="bibr42-1759720X13485503">Dai <italic>et al.</italic> 2009a</xref>; <xref ref-type="bibr" rid="bibr132-1759720X13485503">Pan <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr166-1759720X13485503">Tang <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr167-1759720X13485503">Te <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr198-1759720X13485503">Zhao <italic>et al.</italic> 2010b</xref>, <xref ref-type="bibr" rid="bibr197-1759720X13485503">2011</xref>].</p>
<p>miR-146a, a miRNA targeting signaling proteins and thus negatively regulating innate immune responses, has been reported to be underexpressed in CD4 T cells of patients with SLE [<xref ref-type="bibr" rid="bibr166-1759720X13485503">Tang <italic>et al.</italic> 2009</xref>]. In that study, it was shown that reduced miR-146a expression led to activation of the type 1 interferon (IFN) pathway and that miR-146a levels correlated inversely with SLE disease activity. Another miRNA, miR-125, was also reported to be underexpressed in CD4 T cells of patients with SLE [<xref ref-type="bibr" rid="bibr198-1759720X13485503">Zhao <italic>et al.</italic> 2010b</xref>]. Decreased levels of miR-125a appeared to lead to increased production of an inflammatory chemokine RANTES. Pan and colleagues reported that miR-21 and miR-148a were upregulated in CD4 T cells prepared from both patients with SLE and MRL-lpr mice [<xref ref-type="bibr" rid="bibr132-1759720X13485503">Pan <italic>et al.</italic> 2010</xref>]. These investigators subsequently showed that miR-148a directly and miR-21 indirectly target DNA methyltransferases 1 (DNMT1), suggesting their role in regulating DNA methylation in SLE CD4 T cells [<xref ref-type="bibr" rid="bibr132-1759720X13485503">Pan <italic>et al.</italic> 2010</xref>]. Indeed, overexpression of miR-148a and miR-21 in CD4 T cells resulted in DNA hypomethylation and increased expressed of CD70 and LFA-1. The possibility of intricate cross-regulations of miRNA and DNA methylation has subsequently been confirmed in a study by Zhao and colleagues. They reported that miR-126 was overexpressed in SLE CD4 T cells [<xref ref-type="bibr" rid="bibr197-1759720X13485503">Zhao <italic>et al.</italic> 2011</xref>]. It was further shown that miR-126 targets DNMT1 mRNA and reduced DNMT1 protein expression. Similarly, overexpression of miR-126 in CD4 T cells from healthy individuals led to hypomethylation and consequently overexpression of CD11a (a subunit of LFA-1) and CD70 [<xref ref-type="bibr" rid="bibr197-1759720X13485503">Zhao <italic>et al.</italic> 2011</xref>].</p>
<p>Recently, systematic, microarray-based studies of miRNA expression have been initiated. Te and colleagues performed a study that investigated the expression profile of miRNA in PBMCs and Epstein–Barr virus-transformed B-cell lines derived from SLE patients with nephritis or without nephritis [<xref ref-type="bibr" rid="bibr167-1759720X13485503">Te <italic>et al.</italic> 2010</xref>]. They found that 29 and 50, out of 850 tested, miRNAs were differentially expressed in SLE patients with nephritis of African-American ancestry and of European-American ancestry, respectively. Among these miRNAs, 18 miRNAs were differentially expressed in patients of both racial groups. Another recent study, comparing miRNA expression profiles in PBMCs of SLE patients and healthy controls, showed differential expression of 27 miRNAs out of 365 analyzed [<xref ref-type="bibr" rid="bibr161-1759720X13485503">Stagakis <italic>et al.</italic> 2011</xref>]. It was further shown that the levels of miR-21, miR-25, miR-106b, and miR-148b correlated positively with SLE disease activity, whereas the levels of miR-196a and miR-379 negatively correlated with SLE disease activity. This latter finding suggests a potential role for miRNA profiling as disease activity biomarkers for SLE.</p>
<p>In addition to investigation of miRNAs in blood cells, some investigators also attempted to detect cell-free miRNAs in serum and urine samples from patients with SLE [<xref ref-type="bibr" rid="bibr176-1759720X13485503">Wang <italic>et al.</italic> 2011</xref>, <xref ref-type="bibr" rid="bibr177-1759720X13485503">2012</xref>]. Wang and colleagues reported reduced levels of cell-free miR-146a and miR-155 circulating in the serum of patients with SLE and elevated levels of miR-146a in the urine of patients with SLE, compared to healthy controls. Furthermore, serum miR-146a levels correlated inversely with SLE disease activity and the degree of proteinuria, whereas serum miR-146a and miR-155 levels correlated positively with glomerular filtration rate [<xref ref-type="bibr" rid="bibr176-1759720X13485503">Wang <italic>et al.</italic> 2011</xref>]. The same group subsequently conducted a profiling study of circulating miRNAs in patients with SLE, patients with rheumatoid arthritis, and healthy controls. They found that miR-126 was specifically elevated in the blood of patients with SLE, whereas miR-125a-3p, miR-155, and miR-146a were significantly reduced in patients with SLE [<xref ref-type="bibr" rid="bibr177-1759720X13485503">Wang <italic>et al.</italic> 2012</xref>]. Several other miRNAs (miR-16, miR-223, miR-451, miR-21) were found to be upregulated in both patients with SLE and patients with rheumatoid arthritis. The bioinformatics exploratory analysis implied that most dysregulated circulating miRNAs may be involved in regulating intracellular signal transduction. Taken together, these results suggest that cell-free miRNAs in body fluids may serve as potential biomarkers for SLE.</p>
<p>Recent studies have identified numerous miRNAs that are dysregulated in human patients with SLE and lupus-prone mice. However, it should be cautioned that the results from different studies are not always consistent or reproducible. These discrepancies may originate from the nature of the studies (cross-sectional, small sample size, etc.) and differences in the patient populations (ethnicity, disease severity, duration, manifestations, cohort size, etc.) and the detection methods used. Nevertheless, miRNAs represent a promising group of novel biomarkers for SLE and warrant further investigation.</p>
</sec>
</sec>
<sec id="section7-1759720X13485503">
<title>Cytokine and chemokine biomarkers</title>
<p>With increasing numbers of cytokines and chemokines identified and understanding of cytokine biology improved, these molecules have emerged as important players in the pathogenesis of SLE or as indirect markers reflecting dysregulated immune responses in SLE [<xref ref-type="bibr" rid="bibr1-1759720X13485503">Adhya <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr5-1759720X13485503">Apostolidis <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr44-1759720X13485503">Davis <italic>et al.</italic> 2011</xref>] (<xref ref-type="table" rid="table2-1759720X13485503">Table 2</xref>). This emerging role of cytokines and chemokines has in turn sparked growing attention on their potential as biomarkers and therapeutic targets in SLE.</p>
<table-wrap id="table2-1759720X13485503" position="float">
<label>Table 2.</label>
<caption>
<p>Cytokine and chemokine abnormalities associated with SLE.</p>
</caption>
<graphic alternate-form-of="table2-1759720X13485503" xlink:href="10.1177_1759720X13485503-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Cytokine/Chemokine</th>
<th align="left">Abnormality</th>
<th align="left">Disease Association</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFNα/β</td>
<td>Elevated levels in serum and CSF</td>
<td>CNS and hematological manifestations; fever</td>
</tr>
<tr>
<td>IFN signature</td>
<td>Upregulated expression of IFN-regulated genes</td>
<td>CNS (cerebritis), hematologic, and renal manifestations</td>
</tr>
<tr>
<td colspan="3">IFN-inducible chemokines</td>
</tr>
<tr>
<td> MCP-1 (CCL2)</td>
<td rowspan="7" valign="top">Increased levels in serum and/or urine; increased gene expression</td>
<td>Disease activity/flares</td>
</tr>
<tr>
<td> RANTES (CCL5)</td>
<td>Lupus nephritis</td>
</tr>
<tr>
<td> MIP-3B (CCL19)</td>
<td>NPSLE</td>
</tr>
<tr>
<td> IP-10 (CXCL10)</td>
<td>Hypocomplementemia</td>
</tr>
<tr>
<td> SIGLEC-1</td>
<td>Autoantibodies (anti-dsDNA, anti-U1-RNP; Ro, Sm)</td>
</tr>
<tr>
<td> CXCL1</td>
<td/>
</tr>
<tr>
<td> CXCL16</td>
<td/>
</tr>
<tr>
<td>IFNγ</td>
<td>Elevated serum levels</td>
<td>Disease activity?</td>
</tr>
<tr>
<td>IL-17</td>
<td>Elevated serum levels</td>
<td>Disease activity?</td>
</tr>
<tr>
<td>IL-6</td>
<td>Elevated levels in serum and urine</td>
<td>Disease activity; anti-dsDNA levels; low serum C3/C4; lupus nephritis</td>
</tr>
<tr>
<td>IL-10</td>
<td>Elevated serum levels</td>
<td>Disease activity; anti-dsDNA levels; low serum C3/C4</td>
</tr>
<tr>
<td>IL-12</td>
<td>Elevated or decreased levels reported in different studies</td>
<td>Lupus nephritis (elevated levels in serum and urine)</td>
</tr>
<tr>
<td>IL-15</td>
<td>Elevated serum levels</td>
<td>Disease pathogenesis?</td>
</tr>
<tr>
<td>IL-21</td>
<td>Elevated serum levels</td>
<td>Disease activity; disease pathogenesis?</td>
</tr>
<tr>
<td>IL-2</td>
<td>Decreased serum levels</td>
<td>Disease pathogenesis?</td>
</tr>
<tr>
<td>IL-1</td>
<td>Elevated serum levels</td>
<td>Disease activity</td>
</tr>
<tr>
<td>IL-1 receptor antagonist (IL-1ra)</td>
<td>Decreased serum levels</td>
<td>Lupus nephritis</td>
</tr>
<tr>
<td>BAFF (BLys)</td>
<td>Elevated serum levels</td>
<td>Disease activity</td>
</tr>
<tr>
<td>TNFα</td>
<td>Elevated levels in serum and kidneys</td>
<td>Disease activity; correlated with serum IFNα levels</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1759720X13485503">
<p>BAFF, B-cell activating factor; CNS, central nervous system; CSF, cerebrospinal fluid; IFN, interferon; IL, interleukin; NPSLE, neuropsychiatric systemic lupus erythematosus; SLE, systemic lupus erythematosus; TNF, tumor necrosis factor</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section8-1759720X13485503">
<title>Type I IFNs and IFN-inducible genes and chemokines</title>
<p>Numerous studies, both cross-sectional and longitudinal, have identified various cytokines and chemokines that are associated with SLE disease activity and clinical manifestations. Prominent among these candidate biomarkers is the type 1 IFN system (e.g. IFNα and IFNα-inducible genes and proteins) [<xref ref-type="bibr" rid="bibr39-1759720X13485503">Crow, 2007</xref>; <xref ref-type="bibr" rid="bibr50-1759720X13485503">Elkon and Wiedeman, 2012</xref>; <xref ref-type="bibr" rid="bibr129-1759720X13485503">Obermoser and Pascual, 2010</xref>]. As early as in 1970s, IFNα levels were shown to be elevated in the serum of SLE [<xref ref-type="bibr" rid="bibr67-1759720X13485503">Hooks <italic>et al.</italic> 1979</xref>; <xref ref-type="bibr" rid="bibr190-1759720X13485503">Ytterberg and Schnitzer, 1982</xref>]. The role of IFNα, however, was left underappreciated until the recent decade when gene expression profiling techniques and multiplexed serologic tests advanced considerably. Baechler and colleagues pioneered the use of DNA microarray techniques to study gene expression profiles in PBMCs of SLE patients and found a striking pattern of upregulated IFN-inducible genes (termed the ‘IFN signature’) in a subset of SLE patients [<xref ref-type="bibr" rid="bibr8-1759720X13485503">Baechler <italic>et al.</italic> 2003</xref>]. They further observed that the IFN signature correlated with more severe disease, such as cerebritis, nephritis, and hematological involvement, in those patients. Other investigators have subsequently reported similar findings, including significant associations of enhanced expression of IFN-inducible genes and/or serum levels of IFN-inducible chemokines with increased disease activity, organ involvement, hypocomplementemia, and the presence of autoantibodies specific for dsDNA and RNA-binding proteins (Ro, U1-RNP, and Sm), in both adult and pediatric SLE patients [<xref ref-type="bibr" rid="bibr13-1759720X13485503">Bauer <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr16-1759720X13485503">Bennett <italic>et al.</italic> 2003</xref>; <xref ref-type="bibr" rid="bibr53-1759720X13485503">Feng <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr89-1759720X13485503">Kirou <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr126-1759720X13485503">Nikpour <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr174-1759720X13485503">Vila <italic>et al.</italic> 2007</xref>]. Two independent studies utilizing transcriptome analysis and traditional techniques [enzyme-linked immunosorbent assay (ELISA) and flow cytometry] demonstrated that IP-10 and sialic acid-binding Ig-like lectin 1 (SIGLEC-1) were among the most prominent type 1 IFN-regulated genes/proteins [<xref ref-type="bibr" rid="bibr17-1759720X13485503">Biesen <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr146-1759720X13485503">Rose <italic>et al.</italic> 2012</xref>]. Increased serum levels of IP-10 and SIGLEC-1 were detected in 50% and 86%, respectively, of patients with active SLE [<xref ref-type="bibr" rid="bibr146-1759720X13485503">Rose <italic>et al.</italic> 2012</xref>]. The serum IP-10 and SIGLEC-1 levels correlated positively with disease activity and anti-dsDNA antibody levels, but inversely with serum complement levels [<xref ref-type="bibr" rid="bibr17-1759720X13485503">Biesen <italic>et al.</italic> 2008</xref>]. A pathologic role for IFNα in neuropsychiatric SLE (NPSLE) has recently been postulated [<xref ref-type="bibr" rid="bibr86-1759720X13485503">Karageorgas <italic>et al.</italic> 2011</xref>]. This postulation is based on an early study in which elevated IFNα levels in the cerebrospinal fluid (CSF) were detected in some patients with NPSLE [<xref ref-type="bibr" rid="bibr183-1759720X13485503">Winfield <italic>et al.</italic> 1983</xref>] and a recent study reporting that CSF from patients with NPSLE was capable of inducing higher IFNα production <italic>in vitro</italic> compared with other disease controls [<xref ref-type="bibr" rid="bibr151-1759720X13485503">Santer <italic>et al.</italic> 2009</xref>].</p>
<p>The above-mentioned cross-sectional studies have recently been followed by longitudinal studies. Bauer and colleagues measured IFN-regulated chemokine levels in 267 patients with SLE followed for 1 year (1166 total visits) [<xref ref-type="bibr" rid="bibr14-1759720X13485503">Bauer <italic>et al.</italic> 2009</xref>]. Serum levels of CXCL10 (IP-10), CCL2 (MCP-1), and CCL19 (MIP-3B) were found to correlate strongly with lupus activity, rising at flare and decreasing with remission, and to perform better than currently available laboratory tests. To further determine whether changes in the IFN signature expression correlate with clinical outcomes such as disease flares, a Canadian research group investigated the expression levels of selected IFNα-inducible genes, serological variables, and clinical disease activity [as measured by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)] in 94 SLE patients over a period of 3–12 months [<xref ref-type="bibr" rid="bibr93-1759720X13485503">Landolt-Marticorena <italic>et al.</italic> 2009</xref>]. When analyzed cross-sectionally at a single timepoint, expression levels of IFNα-inducible genes were found to be significantly elevated and associated with high SLEDAI scores, active renal disease, decreased C3 levels, and positive anti-dsDNA and anti-RNA-binding protein autoantibodies. However, when followed over time, no significant correlation between changes in IFNα-inducible gene expression and changes in disease activity, C3 levels, or autoantibody levels was observed. Similarly, Petri and colleagues conducted a study combining both cross-sectional and longitudinal analysis of INFα-regulated gene expression in peripheral blood cells of patients with SLE [<xref ref-type="bibr" rid="bibr134-1759720X13485503">Petri <italic>et al.</italic> 2009</xref>]. A cross-sectional analysis of 66 patients with SLE showed that higher IFN-response (IFNr) scores (calculated based on the expression of three INFα-regulated genes) were associated with greater disease activity. However, the IFNr scores did not significantly differ in 15 patients who were studied before and during flares. An extended longitudinal follow up of 11 patients also showed little change in IFNr scores over time, even with dynamic disease activity changes. These results demonstrate that although IFNr scores appear to be associated with SLE disease activity overall, the IFNr scores of individual patients do not correlate with changes in disease activity.</p>
<p>Taken together, the candidacy of the IFN gene signature/IFN-inducible proteins as biomarkers for monitoring and/or predicting SLE disease activity needs to be further investigated with large-scale multicenter trials.</p>
</sec>
<sec id="section9-1759720X13485503">
<title>Interleukin-17</title>
<p>A growing list of cytokines and soluble forms of cytokine receptors have been identified as potential biomarkers of SLE disease activity in many cross-sectional studies with limited cohort sizes. Among them, cytokines of the IL-17 family have received recent attention [<xref ref-type="bibr" rid="bibr37-1759720X13485503">Crispin and Tsokos, 2010a</xref>]. The IL-17 family consists of IL-17A, IL-17-B, IL-17C, IL-17D, and IL-17F, with IL-17A being the most prominent and well characterized member of the family [<xref ref-type="bibr" rid="bibr131-1759720X13485503">Ouyang <italic>et al.</italic> 2008</xref>]. Elevated serum levels of IL-17A and increased numbers of IL-17-producing cells have been reported in patients with SLE [<xref ref-type="bibr" rid="bibr36-1759720X13485503">Crispin <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr49-1759720X13485503">Doreau <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr157-1759720X13485503">Shah <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr185-1759720X13485503">Wong <italic>et al.</italic> 2000</xref>; <xref ref-type="bibr" rid="bibr188-1759720X13485503">Yang <italic>et al.</italic> 2009</xref>]. IL-17A is mainly produced by CD4+ T helper 17 (T<sub>H</sub>17) cells [<xref ref-type="bibr" rid="bibr90-1759720X13485503">Korn <italic>et al.</italic> 2009</xref>], γδ T cells [<xref ref-type="bibr" rid="bibr128-1759720X13485503">O’Brien <italic>et al.</italic> 2009</xref>], and CD4-CD8- [double negative (DN)] T cells [<xref ref-type="bibr" rid="bibr36-1759720X13485503">Crispin <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr38-1759720X13485503">Crispin and Tsokos, 2010b</xref>]. In SLE, T<sub>H</sub>17 cells and particularly the DN T cells can infiltrate tissues (e.g. the kidneys) and stimulate stromal cells and other immune cells to produce additional cytokines (e.g. IL-6, granulocyte colony stimulating factor, and granulocyte monocyte colony stimulating factor), thereby promoting tissue inflammation and injury [<xref ref-type="bibr" rid="bibr36-1759720X13485503">Crispin <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr131-1759720X13485503">Ouyang <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr194-1759720X13485503">Zhang <italic>et al.</italic> 2009</xref>]. Although elevated serum IL-17 levels have been reported in patients with SLE, the association between elevated IL-17 levels and SLE disease activity is unclear. The potential of IL-17 as an SLE biomarker, therefore, awaits further investigation.</p>
</sec>
<sec id="section10-1759720X13485503">
<title>B-cell activating factor</title>
<p>B-cell activating factor [BAFF; also known as B lymphocyte stimulating factor (BLys), TALL-1, or TNFSF13B] is expressed as a transmembrane protein on monocytes, macrophages, and monocyte-derived dendritic cells [<xref ref-type="bibr" rid="bibr103-1759720X13485503">Mackay and Schneider, 2009</xref>; <xref ref-type="bibr" rid="bibr118-1759720X13485503">Moore <italic>et al.</italic> 1999</xref>]. A soluble form of BAFF, cleaved from the cell surface, is biologically active and critical for B-cell growth and survival [<xref ref-type="bibr" rid="bibr124-1759720X13485503">Nardelli <italic>et al.</italic> 2001</xref>]. Several cross-sectional studies showed that approximately 30% of SLE patients had significantly elevated circulating levels of BAFF/BLys [<xref ref-type="bibr" rid="bibr29-1759720X13485503">Cheema <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr192-1759720X13485503">Zhang <italic>et al.</italic> 2001</xref>]. Elevated BAFF/BLys levels appeared to correlate with increased total IgG and autoantibody (particularly anti-dsDNA) levels [<xref ref-type="bibr" rid="bibr29-1759720X13485503">Cheema <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr133-1759720X13485503">Pers <italic>et al.</italic> 2005</xref>], and, in some studies, with increased disease activity (as measured by SLEDAI) [<xref ref-type="bibr" rid="bibr15-1759720X13485503">Becker-Merok <italic>et al.</italic> 2006</xref>]. A recent study has shown that excessive productions of IFNγ by activated T cells may be responsible for the induction of BAFF/BLyS production by monocytes and macrophages in lupus patients [<xref ref-type="bibr" rid="bibr63-1759720X13485503">Harigai <italic>et al.</italic> 2008</xref>].</p>
<p>To delineate the role of BAFF/BLyS in the long-term immune dysregulation in SLE, Stohl and colleagues conducted a longitudinal observational study in which 68 SLE patients were followed regularly for disease activity (measured using SLEDAI) and serum BAFF/BLyS levels over a period of 147–420 days (median 369 days) [<xref ref-type="bibr" rid="bibr162-1759720X13485503">Stohl <italic>et al.</italic> 2003</xref>]. They found that SLE patients exhibited considerable variability in serum BAFF/BLyS levels with 50% of patients having persistently or intermittently elevated serum BAFF/BLyS levels over the follow-up period. However, changes in serum BAFF/BLyS levels did not correlate with changes in disease activity and/or specific organ involvement in individual patients. In another study, Becker-Merok and colleagues studied clinical disease activity, serological variables, and serum BAFF/BLyS levels in 60 patients with RA and 42 patients with SLE, 19 of whom were followed prospectively over a period of approximately 16 months [<xref ref-type="bibr" rid="bibr15-1759720X13485503">Becker-Merok <italic>et al.</italic> 2006</xref>]. These investigators found that considerably more SLE patients had significantly higher serum BAFF/BLyS levels than did RA patients. They found that serum BAFF/BLyS levels generally correlated with SLEDAI scores in SLE patients in cross-sectional comparison, but did not correlate with changes in disease activity over time.</p>
<p>Since BAFF/BLyS is not known to have direct or immediate proinflammatory activities, changes in serum BAFF/BLyS levels are unlikely to trigger acute inflammatory reactions and disease manifestations. Therefore, the reported lack of correlations between changes in BAFF/BLyS levels and changes in disease activity in SLE patients might not be surprising. However, it is possible that an increase in disease activity may lag behind increases in circulating BLyS levels due to indirect or ‘delayed’ effects of BAFF/BLyS in the systemic immune-inflammatory reactions of SLE. Petri and other investigators have recently conducted a prospective multicenter study that evaluated 254 SLE patients every 3–6 months over a 2-year period [<xref ref-type="bibr" rid="bibr135-1759720X13485503">Petri <italic>et al.</italic> 2008</xref>]. The results showed that plasma BAFF/BLyS levels were associated with anti-dsDNA levels and disease activity [measured using Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI]. Interestingly, multivariate analyses showed that a greater increase in the SELENA-SLEDAI score in the current visit was significantly associated with higher BAFF/BLyS levels at the previous visit. Similarly, a greater increase in the BAFF/BLyS level from the previous visit was associated with a greater SELENA-SLEDAI score in the subsequent follow-up visit. These results suggest a ‘delayed’ relationship between circulating BAFF/BLyS levels and SLE disease activity. Most recently, James and colleagues reported that BAFF/BLyS levels were associated with increased lupus disease activity in White but not in African-American patients who had higher BAFF/BLyS levels regardless of disease activity [<xref ref-type="bibr" rid="bibr144-1759720X13485503">Ritterhouse <italic>et al.</italic> 2011</xref>].</p>
</sec>
<sec id="section11-1759720X13485503">
<title>Other cytokines</title>
<p>Other cytokines, such as IL-6, IL-10, IL-12, IL-15, and IL-21, have also been implicated in the pathogenesis of SLE and proposed as potential biomarkers for SLE disease activity. A study by Chun and colleagues reported that patients with SLE had higher serum levels of IL-1, IL-10, IL-12, and IFNγ, but lower level of IL-2, than healthy controls [<xref ref-type="bibr" rid="bibr31-1759720X13485503">Chun <italic>et al.</italic> 2007</xref>]. Moreover, serum IL-6 and IL-10 levels correlated positively with SLEDAI scores and anti-dsDNA titers but negatively with serum C3 and C4 levels. IL-12 is capable of stimulating the differentiation of  T cells into T<sub>H</sub>1 cells that produce IFNγ. Therefore, IL-12 may be involved in the pathogenesis of SLE indirectly via its effects on cells expressing IL-12 receptors (IL-12R). A recent study reported that patients with SLE have a higher copy number of the IL-12RB gene as compared with healthy controls [<xref ref-type="bibr" rid="bibr191-1759720X13485503">Yu <italic>et al.</italic> 2011</xref>]. A higher copy number of the IL-12RB gene may confer increased sensitivity to IL-12 and hence increased IFNγ production by immune cells. IL-27, a new member of the IL-12 cytokine family, can synergize with IL-12 to induce IFNγ production [<xref ref-type="bibr" rid="bibr7-1759720X13485503">Awasthi <italic>et al.</italic> 2007</xref>]. It has been reported that serum IL-27 levels were lower in SLE patients than in healthy individuals [<xref ref-type="bibr" rid="bibr95-1759720X13485503">Li <italic>et al.</italic> 2010</xref>]. IL-15 and IL-21 are members of the IL-2 cytokine family. IL-15 is involved in the expansion and homeostasis of  T cells and also capable of promoting immunoglobulin isotype switching in B cells [<xref ref-type="bibr" rid="bibr57-1759720X13485503">Gabay and McInnes, 2009</xref>]. Increased serum levels of IL-15 have been reported in SLE patients [<xref ref-type="bibr" rid="bibr6-1759720X13485503">Aringer <italic>et al.</italic> 2001</xref>]. Different from IL-15, IL-21 is also involved in B-cell activation and activation-induced death of B cells [<xref ref-type="bibr" rid="bibr51-1759720X13485503">Ettinger <italic>et al.</italic> 2008</xref>]. Decreased IL-21R expression on B cells has been associated with high autoantibody production and nephritis in SLE patients [<xref ref-type="bibr" rid="bibr114-1759720X13485503">Mitoma <italic>et al.</italic> 2005</xref>].</p>
</sec>
</sec>
<sec id="section12-1759720X13485503">
<title>T-cell-related biomarkers</title>
<p>T cells play crucial effector and regulatory roles in virtually any immune-inflammatory response. T cells of patients with SLE display numerous phenotypic and functional abnormalities, thereby contributing to SLE pathogenesis and serving potentially as a rich source of SLE biomarkers [<xref ref-type="bibr" rid="bibr66-1759720X13485503">Hoffman, 2004</xref>; <xref ref-type="bibr" rid="bibr123-1759720X13485503">Moulton and Tsokos, 2011</xref>] (<xref ref-type="table" rid="table3-1759720X13485503">Table 3</xref>).</p>
<table-wrap id="table3-1759720X13485503" position="float">
<label>Table 3.</label>
<caption>
<p>Novel T-cell-related SLE biomarkers.</p>
</caption>
<graphic alternate-form-of="table3-1759720X13485503" xlink:href="10.1177_1759720X13485503-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Type</th>
<th align="left">Observation</th>
<th align="left">Disease association</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD44v3/CD44v6-expressing T cells</td>
<td>Elevated expression by T cells</td>
<td>Disease activity (SLEDAI scores); anti-dsDNA; lupus nephritis</td>
</tr>
<tr>
<td>KIR-expressing T cells</td>
<td>Aberrant expression on in T cells</td>
<td>Disease activity (SLEDAI scores)</td>
</tr>
<tr>
<td>NKG2D-expression CD4+ T cells</td>
<td>Increased expansion in patients with juvenile-onset SLE</td>
<td>Inverse correlation with disease activity</td>
</tr>
<tr>
<td>CD4-CD8- (double negative) T cells</td>
<td>Significant expansion in the peripheral blood and kidneys; capable of producing IL-17</td>
<td>Lupus nephritis</td>
</tr>
<tr>
<td>Altered lipid raft-expressing T cells</td>
<td>Increased levels of GM1 and clustered lipid raft in the membrane of SLE T cells</td>
<td>Disease pathogenesis?</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1759720X13485503">
<p>IL, interleukin; KIR, killer immunoglobulin-like receptor; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section13-1759720X13485503">
<title>Unique T-cell subsets</title>
<p>A heightened capacity of T cells to adhere and migrate into inflamed tissue may lead to organ damage in patients with SLE. A recent study has shown that surface expression of CD44 (an adhesion molecule) and its variant isoforms CD44v3 and CD44v6 were elevated on T cells of patients with SLE [<xref ref-type="bibr" rid="bibr34-1759720X13485503">Crispin <italic>et al.</italic> 2010a</xref>]. Significantly, T-cell surface levels of CD44v3 and CD44v6 were found to be correlated with the SLEDAI score, positivity of anti-dsDNA, and the presence of lupus nephritis. These results suggest that expression levels of CD44v3 and CD44v6 on T cells may serve as biomarkers for SLE disease activity [<xref ref-type="bibr" rid="bibr34-1759720X13485503">Crispin <italic>et al.</italic> 2010a</xref>]. Recently, it has also been reported that killer cell-Ig like receptors (KIR), surface molecules originally identified on natural killer (NK) cells, were aberrantly expressed by T cells of patients with SLE and that the expression of T-cell surface KIR was proportional to the SLEDAI score [<xref ref-type="bibr" rid="bibr11-1759720X13485503">Basu <italic>et al.</italic> 2009</xref>]. These studies implicate the potential of frequencies of KIR-expressing T cells and T-cell expression levels as disease activity biomarkers for SLE. Another potential T-cell-relevant disease activity biomarker was suggested by a recent study that reported increased expansion of a subpopulation of CD4+ T cells that express the NKG2D receptor and display suppressive/regulatory activity in patients with juvenile-onset SLE; the frequencies of such ‘suppressive/regulatory’ NKG2D+CD4+ T cells were correlated inversely with disease activity [<xref ref-type="bibr" rid="bibr43-1759720X13485503">Dai <italic>et al.</italic> 2009b</xref>].</p>
<p>DN T cells, which lack surface expression of CD4 and CD8, constitute a small population (&lt;5% of T cells) in healthy individuals, but are significantly expanded in patients with SLE [<xref ref-type="bibr" rid="bibr36-1759720X13485503">Crispin <italic>et al.</italic> 2008</xref>]. A recent study showed that these cells can secrete cytokines such as IL-17 and IL-1β, induce anti-dsDNA antibody production by autoreactive B cells, and infiltrate the kidneys of patients with lupus nephritis [<xref ref-type="bibr" rid="bibr36-1759720X13485503">Crispin <italic>et al.</italic> 2008</xref>]. Thus, the frequency of DN T cells in the peripheral blood might serve as a surrogate biomarker of lupus nephritis.</p>
</sec>
<sec id="section14-1759720X13485503">
<title>Other potential T-cell-based biomarkers</title>
<p>Previous studies have demonstrated multiple abnormalities at different levels of the T-cell receptor (TCR) signaling cascade and downstream in T cells derived from patients with SLE [<xref ref-type="bibr" rid="bibr123-1759720X13485503">Moulton and Tsokos, 2011</xref>]. It has been shown that the fundamental defect may be linked to alterations in the structure and dynamics of lipid rafts within the plasma membrane of lupus T cells [<xref ref-type="bibr" rid="bibr80-1759720X13485503">Jury <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr83-1759720X13485503">Kabouridis and Jury, 2008</xref>]. Lipid rafts are cholesterol- and glycosphingolipid-rich membrane microdomains that facilitate and orchestrate close interactions between molecules that are critical in signal transduction [<xref ref-type="bibr" rid="bibr62-1759720X13485503">Harder, 2004</xref>]. Several investigators have shown that, as compared to T cells derived from control mice or healthy individuals, T cells derived from lupus-prone mice or patients with SLE express increased levels of glycosphingolipid GM1 and possess higher amounts of clustered lipid rafts that are associated with unusual components such as FcRγ activated Syk kinase, and CD45 [<xref ref-type="bibr" rid="bibr48-1759720X13485503">Dong <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr82-1759720X13485503">Jury <italic>et al.</italic> 2004</xref>; <xref ref-type="bibr" rid="bibr92-1759720X13485503">Krishnan <italic>et al.</italic> 2004</xref>]. Furthermore, it was recently shown that injection of lupus-prone mice with Cholera Toxin B, a component of <italic>Vibrio cholerae</italic> capable of binding to GM1, induced aggregation of lipid rafts in T cells and consequently accelerated lupus development in those mice [<xref ref-type="bibr" rid="bibr46-1759720X13485503">Deng and Tsokos, 2008</xref>]. Conversely, statins (inhibitors of HMG-CoA reductase), which decrease cholesterol synthesis and thus can modify lipid raft components, have been shown to restore signaling defects characteristic of SLE T cells [<xref ref-type="bibr" rid="bibr81-1759720X13485503">Jury <italic>et al.</italic> 2006</xref>]. Taken together, these studies support a pivotal role for altered lipid rafts in dysregulated T cell signaling in SLE and imply potential utility of levels of T-cell-associated altered lipid rafts as surrogate biomarkers for SLE disease activity.</p>
</sec>
</sec>
</sec>
<sec id="section15-1759720X13485503">
<title>Biomarkers for lupus nephritis</title>
<p>SLE can affect virtually any tissue or organ. However, not all organs will be affected simultaneously, and the involvement of a specific organ will not necessarily be manifested in the same manner in different patients. The manifestations of specific organ involvement of a given patient may also vary over time. This clinical heterogeneity of SLE poses a great demand for biomarkers that can differentiate, determine, monitor, stratify and/or predict organ-specific involvement in patients with SLE.</p>
<p>Of the myriad manifestations of SLE, renal involvement is one of the most common and it continues to cause significant morbidity and mortality. Lupus nephritis occurs in 25–50% of adult patients with SLE [<xref ref-type="bibr" rid="bibr24-1759720X13485503">Cameron, 1999</xref>] and 80% of pediatric patients with SLE [<xref ref-type="bibr" rid="bibr178-1759720X13485503">Watson and Beresford, 2012</xref>]. Among those patients, 25% and 40% of adult and pediatric patients, respectively, may progress to end-stage renal disease. Improved methods for detecting lupus nephritis would allow earlier treatment, which may prevent irreversible kidney damage and thwart declines in renal function.</p>
<p>In lieu of invasive and impractical serial renal biopsies, creatinine clearance, urine protein level, urine sediment, serum C3 and C4 levels, serum creatinine level, and anti-dsDNA titers have for decades been used to follow the onset, course, and severity of lupus nephritis, yet it is generally recognized that these measurements are inadequate. Current efforts are focused on identification of more sensitive and specific biomarkers to diagnose and monitor renal disease in both adult and pediatric patients with SLE, with the hope to optimize synchronization of treatment with active disease, distinguish active inflammation from irreversible damage, and to facilitate development of new therapeutics through clinical trials [<xref ref-type="bibr" rid="bibr1-1759720X13485503">Adhya <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr116-1759720X13485503">Mok, 2010</xref>; <xref ref-type="bibr" rid="bibr149-1759720X13485503">Rovin and Zhang, 2009</xref>] (<xref ref-type="table" rid="table4-1759720X13485503">Table 4</xref>).</p>
<table-wrap id="table4-1759720X13485503" position="float">
<label>Table 4.</label>
<caption>
<p>Summary of biomarkers for lupus nephritis.</p>
</caption>
<graphic alternate-form-of="table4-1759720X13485503" xlink:href="10.1177_1759720X13485503-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td><bold>Traditional Biomarkers</bold></td>
</tr>
<tr>
<td> Serum Creatinine levels</td>
</tr>
<tr>
<td> Serum C3/C4 levels</td>
</tr>
<tr>
<td> Anti-dsDNA levels</td>
</tr>
<tr>
<td> Urine protein levels</td>
</tr>
<tr>
<td> Urine sediments</td>
</tr>
<tr>
<td> Kidney biopsy</td>
</tr>
<tr>
<td><bold>Candidate Biomarkers (Serum, peripheral blood, and kidney)</bold></td>
</tr>
<tr>
<td> Anti-nucleosome antibodies (serum)</td>
</tr>
<tr>
<td> Anti-C1q antibodies (serum)</td>
</tr>
<tr>
<td> Complement C4d (kidney biopsy)</td>
</tr>
<tr>
<td> Complement C4d (erythrocyte-bound; peripheral blood)</td>
</tr>
<tr>
<td><bold>Candidate Biomarkers (Urinary proteins)</bold></td>
</tr>
<tr>
<td> Monocyte chemoattractant protein-1 (MCP-1)</td>
</tr>
<tr>
<td> Neutrophil gelatinase-associated lipocalin (NGAL)</td>
</tr>
<tr>
<td> Tumor necrosis factor-like weak inducer of apoptosis (TWEAK)</td>
</tr>
<tr>
<td> Transferrin (TF)</td>
</tr>
<tr>
<td> α1-acid glycoprotein (AGP; AAG)</td>
</tr>
<tr>
<td> Ceruloplasmin (CP)</td>
</tr>
<tr>
<td> Lipocalin-type prostaglandin D-synthetase (L-PGDS)</td>
</tr>
<tr>
<td> Hepcidin</td>
</tr>
<tr>
<td> Tumor growth factor β (TGFβ)</td>
</tr>
</tbody>
</table>
</table-wrap>
<sec id="section16-1759720X13485503">
<title>Antinucleosome antibodies</title>
<p>The use of autoantibodies other than anti-dsDNA in monitoring and preferably predicting renal disease in patients with SLE has been explored extensively during the past several decades. Among those autoantibodies, antichromatin/antinucleosome antibodies [<xref ref-type="bibr" rid="bibr23-1759720X13485503">Bruns <italic>et al.</italic> 2000</xref>; <xref ref-type="bibr" rid="bibr59-1759720X13485503">Gomez-Puerta <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr91-1759720X13485503">Koutouzov <italic>et al.</italic> 2004</xref>], along with anti-C1q antibodies [<xref ref-type="bibr" rid="bibr136-1759720X13485503">Pickering and Botto, 2010</xref>; <xref ref-type="bibr" rid="bibr139-1759720X13485503">Potlukova and Kralikova, 2008</xref>] (see the next section), have shown some promise as biomarkers of renal involvement. Chromatin, the DNA-histone complex found in the nucleus of eukaryotic cells, is organized into a repeating series of nucleosomes. Previous studies have demonstrated that the nucleosome is a major autoantigen targeted by T and B cells in SLE [<xref ref-type="bibr" rid="bibr23-1759720X13485503">Bruns <italic>et al.</italic> 2000</xref>; <xref ref-type="bibr" rid="bibr115-1759720X13485503">Mohan <italic>et al.</italic> 1993</xref>]. Antinucleosome antibodies are reportedly present in 70–100% of patients with SLE, and are fairly sensitive (48–100%) and highly specific (90–99%) for SLE [<xref ref-type="bibr" rid="bibr26-1759720X13485503">Cervera <italic>et al.</italic> 2003</xref>; <xref ref-type="bibr" rid="bibr27-1759720X13485503">Chabre <italic>et al.</italic> 1995</xref>; <xref ref-type="bibr" rid="bibr59-1759720X13485503">Gomez-Puerta <italic>et al.</italic> 2008</xref>]. Among SLE patients, antinucleosome antibodies are more likely to be detected in patients with nephritis and may serve as a useful biomarker in the diagnosis of active lupus nephritis [<xref ref-type="bibr" rid="bibr26-1759720X13485503">Cervera <italic>et al.</italic> 2003</xref>; <xref ref-type="bibr" rid="bibr60-1759720X13485503">Grootscholten <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr61-1759720X13485503">Gutierrez-Adrianzen <italic>et al.</italic> 2006</xref>].</p>
<p>Moreover, some investigators reported that antinucleosome antibodies could be found in patients who consistently tested negative for anti-dsDNA antibodies and that a significant fraction of those patients indeed had renal disease [<xref ref-type="bibr" rid="bibr112-1759720X13485503">Min <italic>et al.</italic> 2002</xref>], suggesting that antinucleosome antibodies may serve as a sensitive marker for renal involvement in the absence of anti-dsDNA. A prospective controlled study was recently conducted with 52 patients with active proliferative lupus nephritis [<xref ref-type="bibr" rid="bibr60-1759720X13485503">Grootscholten <italic>et al.</italic> 2007</xref>]. It was found that patients with high titers of antinucleosome antibodies had significantly higher disease activity; the levels of antinucleosome antibodies rapidly declined after treatment. Similarly, another study followed a group of SLE patients with new-onset lupus nephritis for up to 2 years [<xref ref-type="bibr" rid="bibr106-1759720X13485503">Manson <italic>et al.</italic> 2009</xref>]. Those investigators showed that antinucleosome levels associated positively with decreasing renal function (measured by urine protein/creatinine ratio and serum albumin level), and the levels of antinucleosome antibodies significantly decreased during remission of lupus nephritis.</p>
<p>Although many studies including those discussed here have reported the promise of antinucleosome antibodies, it should be cautioned that another study showed that antinucleosome antibodies are highly prevalent in both SLE patients with (89%) or without (80%) active proliferative nephritis and have limited value in distinguishing these two subgroups of patients [<xref ref-type="bibr" rid="bibr18-1759720X13485503">Bigler <italic>et al.</italic> 2008</xref>]. Nevertheless, these studies collectively provide substantial, but not definitive, evidence that antinucleosome antibodies may be more sensitive and have greater diagnostic efficacy than anti-dsDNA for active disease, especially nephritis, in SLE patients.</p>
<sec id="section17-1759720X13485503">
<title>Anti-C1q antibodies</title>
<p>Anti-C1q antibodies are mostly of the IgG subtype that react with epitopes present within the collagen-like tail of C1q. Although anti-C1q antibodies can be detected in a small proportion of healthy individuals (3-5%), they are more common in patients with autoimmune disorders such as hypocomplementemic urticarial vasculitis (100%) and SLE (17-63%) [<xref ref-type="bibr" rid="bibr159-1759720X13485503">Sinico <italic>et al.</italic> 2009</xref>]. A significant correlation between the presence of anti-C1q antibodies and renal disease in SLE has been reported [<xref ref-type="bibr" rid="bibr68-1759720X13485503">Horak <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr69-1759720X13485503">Horvath <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr107-1759720X13485503">Marto <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr120-1759720X13485503">Moroni <italic>et al.</italic> 2001</xref>], with positive predictive value and negative predictive to be 58% and 100%, respectively [<xref ref-type="bibr" rid="bibr120-1759720X13485503">Moroni <italic>et al.</italic> 2001</xref>]. Therefore, the absence of anti-C1q antibodies has been suggested as an indicator for excluding a diagnosis of lupus nephritis [<xref ref-type="bibr" rid="bibr171-1759720X13485503">Trendelenburg <italic>et al.</italic> 1999</xref>, <xref ref-type="bibr" rid="bibr170-1759720X13485503">2006</xref>]. Significant correlations between anti-C1q titers and active lupus nephritis have also been reported [<xref ref-type="bibr" rid="bibr3-1759720X13485503">Akhter <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr120-1759720X13485503">Moroni <italic>et al.</italic> 2001</xref>; <xref ref-type="bibr" rid="bibr170-1759720X13485503">Trendelenburg <italic>et al.</italic> 2006</xref>], with a sensitivity of 44-100% and a specificity of 70-92% reported by Moroni and colleagues [<xref ref-type="bibr" rid="bibr120-1759720X13485503">Moroni <italic>et al.</italic> 2001</xref>]. Another study reported the detection of anti-C1q antibodies in SLE patients who did not have a history of renal disease but eventually developed lupus nephritis [<xref ref-type="bibr" rid="bibr107-1759720X13485503">Marto <italic>et al.</italic> 2005</xref>]. The detection of anti-C1q and an increase in anti-C1q antibodies have been suggested to predict renal flares [<xref ref-type="bibr" rid="bibr111-1759720X13485503">Meyer <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr120-1759720X13485503">Moroni <italic>et al.</italic> 2001</xref>, <xref ref-type="bibr" rid="bibr119-1759720X13485503">2009</xref>]. For example, Moroni and colleagues followed 228 patients with lupus nephritis for 6 years and found that elevation of anti-C1q levels predicted renal flares in patients with proliferative lupus nephritis, with a sensitivity of 81% and a specificity of 71% [<xref ref-type="bibr" rid="bibr119-1759720X13485503">Moroni <italic>et al.</italic> 2009</xref>]. Some investigators suggested that the prediction value would be further enhanced when both anti-C1q and anti-dsDNA were measured [<xref ref-type="bibr" rid="bibr108-1759720X13485503">Matrat <italic>et al.</italic> 2011</xref>]. Moreover, it has been reported that levels of anti-C1q antibodies decreased after successful treatment of lupus nephritis [<xref ref-type="bibr" rid="bibr170-1759720X13485503">Trendelenburg <italic>et al.</italic> 2006</xref>].</p>
<p>Taken together, these recent studies demonstrate a strong correlation between the presence of anti-C1q antibodies and lupus nephritis, and suggest that anti-C1q determination may serve as a noninvasive biomarker (<italic>versus</italic> the invasive renal biopsy) to monitor renal involvement and/or predict renal flares [<xref ref-type="bibr" rid="bibr136-1759720X13485503">Pickering and Botto, 2010</xref>; <xref ref-type="bibr" rid="bibr159-1759720X13485503">Sinico <italic>et al.</italic> 2009</xref>].</p>
</sec>
<sec id="section18-1759720X13485503">
<title>Complement C4d</title>
<p>An expanding literature has demonstrated the utility of histologic identification of complement C4d as an informative biomarker of transplant allograft rejection. Similarly, investigators from the Netherlands have demonstrated a strong relationship between the intensity of glomerular C4d staining and the presence of microthrombi in patients with lupus nephritis (present in seven of eight patients) [<xref ref-type="bibr" rid="bibr32-1759720X13485503">Cohen <italic>et al.</italic> 2008</xref>]. Most recently, a prospective assessment was performed to determine the potential value of cell-bound C4d as biomarkers of lupus nephritis [<xref ref-type="bibr" rid="bibr12-1759720X13485503">Batal <italic>et al.</italic> 2012</xref>]. Histologic identification of C4d on renal biopsies was compared with the results of a cell-bound complement activation product (CB-CAP) assay panel in 15 patients with lupus nephritis, 239 lupus patients without nephritis and 13 patients with nonlupus nephritis. Patients with lupus nephritis had higher glomerular C4d scores, and also had significantly higher levels of erythrocyte-bound C4s and reticulocyte-bound C4d than the two control groups. SLE patients with lupus nephritis were also more likely to have C4d bound on platelets, as compared with SLE patients without lupus nephritis. Erythrocyte-bound C4d levels correlated with the National Institutes of Health (NIH) activity index. These findings suggest a potential role of circulating cell-bound C4d as a noninvasive biomarker for lupus nephritis.</p>
</sec>
</sec>
<sec id="section19-1759720X13485503">
<title>Urinary chemokine/cytokine biomarkers</title>
<p>Serum and plasma are easy to prepare from patients and have been widely used in developing novel biomarkers for lupus nephritis. However, biological changes in the serum or plasma may not reflect fully and timely the local situation within a specific organ such as the kidneys. Urine, in contrast, may serve as a window looking into the pathological changes in inflamed kidneys in real-time. Significant progress has been made in the discovery of novel urinary biomarkers for lupus nephritis.</p>
<sec id="section20-1759720X13485503">
<title>Monocyte chemoattractant protein-1</title>
<p>Monocyte chemoattractant protein-1 (MCP-1) participates in the pathogenesis of lupus nephritis. A number of earlier studies showed that urinary MCP-1 (uMCP-1) levels were elevated in patients with active nephritis and declined after immunosuppressive treatment [<xref ref-type="bibr" rid="bibr127-1759720X13485503">Noris <italic>et al.</italic> 1995</xref>; <xref ref-type="bibr" rid="bibr147-1759720X13485503">Rovin <italic>et al.</italic> 1996</xref>; <xref ref-type="bibr" rid="bibr175-1759720X13485503">Wada <italic>et al.</italic> 1996</xref>]. Several more recent studies, both cross-sectional and longitudinal, have confirmed those findings [<xref ref-type="bibr" rid="bibr87-1759720X13485503">Kiani <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr148-1759720X13485503">Rovin <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr168-1759720X13485503">Tian <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr173-1759720X13485503">Tucci <italic>et al.</italic> 2004</xref>]. For example, in a study conducted by Rovin and colleagues [<xref ref-type="bibr" rid="bibr148-1759720X13485503">Rovin <italic>et al.</italic> 2005</xref>], it was shown that uMCP-1 level was a sensitive indicator for renal flare, with 73% of the uMCP-1 levels measured at renal flares higher than the 95th percentile of the disease controls. uMCP-1 levels did not correlate with extrarenal disease activity. Moreover, uMCP-1 levels increased as early as 2–4 months before renal flares, suggesting that uMCP-1 may serve as a biomarker for predicting impending renal flares. Similarly, uMCP-1 levels have been shown to elevate in pediatric patients with lupus nephritis and to be able to differentiate patients with active or inactive renal disease [<xref ref-type="bibr" rid="bibr179-1759720X13485503">Watson <italic>et al.</italic> 2012</xref>]. These results, collectively, indicate that urinary levels of MCP-1 protein and urinary MCP-1 mRNA levels are promising biomarker candidates due to specificity for renal activity, sensitivity in predicting renal flares and the capacity to reflect both the severity of flares, and the proliferative nature of the histology [<xref ref-type="bibr" rid="bibr28-1759720X13485503">Chan <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr87-1759720X13485503">Kiani <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr148-1759720X13485503">Rovin <italic>et al.</italic> 2005</xref>].</p>
</sec>
<sec id="section21-1759720X13485503">
<title>Neutrophil gelatinase-associated lipocalin</title>
<p>Neutrophil gelatinase-associated lipocalin (NGAL; lipocalin-2) is a small glycoprotein that functions as a carrier for cellular iron transport, apoptosis, and tissue differentiation. NGAL is constitutively produced at low levels in the kidneys, but is upregulated following inflammation, ischemia, and infection [<xref ref-type="bibr" rid="bibr20-1759720X13485503">Bolignano <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr113-1759720X13485503">Mishra <italic>et al.</italic> 2003</xref>; <xref ref-type="bibr" rid="bibr154-1759720X13485503">Schwartz <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr169-1759720X13485503">Trachtman <italic>et al.</italic> 2006</xref>]. Associations of rising serum and urinary NGAL levels (uNGAL) with acute renal injury have been shown in both adult and pediatric patients [<xref ref-type="bibr" rid="bibr20-1759720X13485503">Bolignano <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr113-1759720X13485503">Mishra <italic>et al.</italic> 2003</xref>; <xref ref-type="bibr" rid="bibr154-1759720X13485503">Schwartz <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr169-1759720X13485503">Trachtman <italic>et al.</italic> 2006</xref>]. In lupus nephritis, it was postulated that injured tubular cells, infiltrating neutrophils, or inflamed vasculature are the sources of uNGAL [<xref ref-type="bibr" rid="bibr22-1759720X13485503">Brunner <italic>et al.</italic> 2006</xref>]. Cross-sectional as well as longitudinal studies have demonstrated the promise of uNAGL as a biomarker of lupus nephritis in both pediatric and adult patients with SLE [<xref ref-type="bibr" rid="bibr22-1759720X13485503">Brunner <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr65-1759720X13485503">Hinze <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr138-1759720X13485503">Pitashny <italic>et al.</italic> 2007</xref>; <xref ref-type="bibr" rid="bibr150-1759720X13485503">Rubinstein <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr165-1759720X13485503">Suzuki <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr187-1759720X13485503">Yang <italic>et al.</italic> 2012</xref>]. In a cross-sectional study of pediatric patients by Brunner and colleagues, uNGAL levels were significantly elevated in patients with lupus nephritis; increased uNGAL levels were associated with renal SLE disease activity scores and not with global damage or extrarenal disease activity [<xref ref-type="bibr" rid="bibr22-1759720X13485503">Brunner <italic>et al.</italic> 2006</xref>]. A cross-sectional study of adult patients with lupus nephritis generated similar findings [<xref ref-type="bibr" rid="bibr138-1759720X13485503">Pitashny <italic>et al.</italic> 2007</xref>]. However, it should be pointed out that conflicting reports regarding the association of uNGAL with lupus nephritis in adult patients have been published recently [<xref ref-type="bibr" rid="bibr88-1759720X13485503">Kiani <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr187-1759720X13485503">Yang <italic>et al.</italic> 2012</xref>]. Nevertheless, the potential of both serum and urinary NGAL as biomarkers for lupus nephritis is best reflected by longitudinal studies demonstrating the capacity to predict exacerbation of renal disease and flares [<xref ref-type="bibr" rid="bibr150-1759720X13485503">Rubinstein <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr165-1759720X13485503">Suzuki <italic>et al.</italic> 2008</xref>].</p>
</sec>
<sec id="section22-1759720X13485503">
<title>Tumor necrosis factor-like weak inducer of apoptosis</title>
<p>Tumor necrosis factor like weak inducer of apoptosis (TWEAK) is a multifunctional cytokine that belongs to the tumor necrosis factor (TNF) superfamily. The expression of TWEAK has been shown to increase dramatically during inflammation and injury [<xref ref-type="bibr" rid="bibr184-1759720X13485503">Winkles, 2008</xref>]. In lupus nephritis, it is possible that TWEAK may induce the production of other proinflammatory cytokines and chemokines and thus propagate tissue inflammatory injury [<xref ref-type="bibr" rid="bibr58-1759720X13485503">Gao <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr152-1759720X13485503">Sanz <italic>et al.</italic> 2008</xref>]. Urinary TWEAK (uTWEAK) levels were shown by Schwartz and colleagues in a cross-sectional study to be significantly higher in SLE patients with active nephritis as compared with those with inactive or no nephritis [<xref ref-type="bibr" rid="bibr156-1759720X13485503">Schwartz <italic>et al.</italic> 2006</xref>]. In addition, uTWEAK levels correlated with anti-dsDNA, serum C3 and C4, uMCP-1 and renal disease activity scores. A subsequent multicenter longitudinal study by this same group further demonstrated the potential value of uTWEAK which was superior to the current standards anti-dsDNA and serum complement levels in differentiating lupus nephritis from nonrenal lupus activity [<xref ref-type="bibr" rid="bibr155-1759720X13485503">Schwartz <italic>et al.</italic> 2009</xref>].</p>
</sec>
</sec>
<sec id="section23-1759720X13485503">
<title>Biomarkers predicting histopathologic features of lupus nephritis</title>
<p>Kidney biopsy is currently the gold standard for diagnosing, classifying, and guiding the treatment of lupus nephritis. It standardizes histological classification of lupus nephritis, enables direct assessment of the presence and severity of acute changes due to active lupus nephritis, and provides information of the chronicity of lupus nephritis. However, the invasive nature of kidney biopsy limits its frequent use in monitoring the disease progression and treatment response. Therefore, noninvasive and sensitive biomarkers that might reveal specific histopathologic features of lupus nephritis are in great need.</p>
<p>The associations of serum antinucleosome and anti-C1q levels with renal histopathologic features have recently been reported [<xref ref-type="bibr" rid="bibr30-1759720X13485503">Chen <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr73-1759720X13485503">Hung <italic>et al.</italic> 2011</xref>]. Hung and colleagues conducted a cross-sectional study with 36 SLE patients with biopsy-proven proliferative lupus nephritis and 14 patients with non-renal SLE [<xref ref-type="bibr" rid="bibr73-1759720X13485503">Hung <italic>et al.</italic> 2011</xref>]. These investigators found that serum levels of antinucleosome antibodies were significantly elevated in patients with lupus nephritis and correlated with SLE disease activity measured by the British Isles Lupus Assessment Group (BILAG) index. The serum antinucleosome antibody levels correlated positively with the histological activity index of lupus nephritis (<italic>r</italic>(s) = 0.368, <italic>p</italic> &lt; 0.05), but not with the chronicity index. In another cross-sectional study involving 52 patients who had biopsy-proven lupus nephritis, serum anti-C1q levels were found to correlate positively with the scores of the SLEDAI, anti-dsDNA antibody, and antinucleosome antibody [<xref ref-type="bibr" rid="bibr30-1759720X13485503">Chen <italic>et al.</italic> 2012</xref>]. The prevalence of anti-C1q was found to be higher in patients with proliferative lupus nephritis [World Health Organization (WHO) class III and class IV] than those with mesangial lupus nephritis (class II), although the difference did not reach statistical significance. The serum anti-C1q levels were highest in patients with class IV lupus nephritis. Furthermore, the anti-C1q levels correlated positively with renal activity indices but negatively with chronicity indices. These findings suggest that serum anti-C1q antibody may be a valuable noninvasive biomarker for prediction of histopathologic characteristics of lupus nephritis.</p>
<p>Following the identification of several promising urinary biomarkers for diagnosing and differentiating active <italic>versus</italic> inactive lupus nephritis, investigators examined the relationship between those urinary biomarkers and histological features of lupus nephritis. In a recent study, Brunner and colleagues assayed several established markers (anti-dsDNA, serum C3, C4, creatinine, urinary protein:creatinine ratio, etc.) and urinary biomarkers [MCP-1, NGAL, lipocalin-type prostaglandin D-synthetase (L-PGDS), α1-acid-blycoprotein (AAG/AGP), transferrin (TF), and ceruloplasmin (CP)] in urine samples from 76 SLE patients collected within 2 months of kidney biopsy [<xref ref-type="bibr" rid="bibr21-1759720X13485503">Brunner <italic>et al.</italic> 2012</xref>]. These urinary biomarkers were compared with histopathologic features of the kidney biopsy (mesangial expansion, capillary proliferation, crescent formation, wire loops, fibrosis, etc.). Statistical analyses included nonparametric analysis and area under the receiver operating characteristic curve (AUC) calculation. The results revealed that differential increases in levels of urinary biomarkers in patients with active lupus nephritis appeared to reflect specific histologic features in the kidneys. Specifically, the combination of urinary MCP-1, AAG, and CP levels and protein:creatinine ratio performed well in predicting lupus nephritis activity (AUC = 0.85). On the other hand, NGAL together with MCP-1 and creatinine clearance appeared to be a valuable indicator of lupus nephritis chronicity (AUC = 0.83). The combined panel of MCP-1, AAG, TF, creatinine clearance, and serum C4 was shown to be a potential biomarker for membranous nephritis (AUC = 0.75).</p>
<p>Collectively, these studies suggest that panels of serum and urinary assays hold promise as potential noninvasive biomarkers for monitoring the activity, chronicity, and type of lupus nephritis.</p>
</sec>
<sec id="section24-1759720X13485503">
<title>SLE biomarker panels</title>
<p>Undoubtedly, no single biomarker will be sufficient ultimately to diagnose, monitor and stratify all patients with SLE. Thus, investigations have recently evolved toward discovery and validation of lupus biomarker ‘panels’. One approach in this regard has been technology-driven with the use of microarrays or proteomics for identifying novel gene or protein ‘biosignatures’ of SLE such as that discussed above for lupus nephritis [<xref ref-type="bibr" rid="bibr21-1759720X13485503">Brunner <italic>et al.</italic> 2012</xref>]. Additional ongoing developments on this front are discussed briefly here.</p>
</sec>
<sec id="section25-1759720X13485503">
<title>Biomarker panels for diagnosis and disease activity monitoring of SLE</title>
<p>Recognizing the importance of aberrant T-cell function in SLE, a gene expression array consisting of 30 genes thought to contribute to the pathogenesis of SLE has recently been developed. To examine the utility of this T cell gene expression array, an initial study was conducted with 10 patients with SLE, 6 patients with rheumatoid arthritis, and 19 healthy individuals [<xref ref-type="bibr" rid="bibr79-1759720X13485503">Juang <italic>et al.</italic> 2011</xref>]. The results showed that the gene expression array could faithfully represent the expression levels of different genes. Moreover, principal component analysis (PCA) was used to evaluate the contribution of the arrayed genes to diagnosis and stratification. PCA of gene expression levels showed that SLE samples were distinguished from samples of RA and healthy individual. Notably, individual principal components appeared to define specific disease parameters such as arthritis and proteinuria. These results suggest potential for this T-cell gene expression as lupus biomarkers for diagnosis and stratification. Further validation, using larger cohorts of patients with lupus compared with patients with other lupus-like diseases is warranted.</p>
<p>Another gene expression-based search for biomarkers of autoimmune disease involved profiling the transcriptomes of purified CD8 T cells [<xref ref-type="bibr" rid="bibr109-1759720X13485503">McKinney <italic>et al.</italic> 2010</xref>]. McKinney and colleagues identified a subset of genes associated with a poor prognosis in patients with SLE. This subset of genes is enriched for genes involved in TCR signaling, IL-7 receptor signaling, and memory T-cell phenotype. They further showed that these subgroups of genes can be identified by measuring the expression of only three representative genes. These findings suggest the prospect of a streamlined version of gene expression-based biomarkers that might be used for identifying patients with poor prognosis and thus for personalized treatment of those patients.</p>
<p>A more recent study investigated the value of a biomarker panel consisting of traditional markers (e.g. ANA and anti-dsDNA) and the newly developed CB-CAP biomarkers [<xref ref-type="bibr" rid="bibr97-1759720X13485503">Liu <italic>et al.</italic> 2010</xref>]. In this multicenter, cross-sectional study, a total of 593 subjects (210 SLE patients, 178 patients with other rheumatic diseases, and 205 healthy individuals) were enrolled [<xref ref-type="bibr" rid="bibr84-1759720X13485503">Kalunian <italic>et al.</italic> 2012</xref>]. Erythrocyte-bound C4d (E-C4d), B-cell-bound C4d (B-C4d), ANA, and anti-mutated citrullinated vimentin antibody (anti-MCV) were measured and an index score system corresponding to the weighted sum of these four markers was developed. It was reported that a positive index score correctively categorized 72% of SLE patients. Furthermore, the sensitivity and specificity of the combination of anti-dsDNA and index score positivity in differentiating SLE from other rheumatic disease was 80% and 87%, respectively. These results support the use a biomarker panel combining anti-dsDNA, ANA, anti-MCV, E-C4d, and B-C4d for the diagnosis of SLE. This is the only biomarker panel validated to date for lupus diagnosis.</p>
<sec id="section26-1759720X13485503">
<title>Composite urinary biomarkers for lupus nephritis</title>
<p>The proteomics approach has recently been taken to identify protein markers/profiles that can differentiate SLE with or without nephritis or differentiate active lupus nephritis from inactive lupus [<xref ref-type="bibr" rid="bibr122-1759720X13485503">Mosley <italic>et al.</italic> 2006</xref>; <xref ref-type="bibr" rid="bibr163-1759720X13485503">Suzuki <italic>et al.</italic> 2007</xref>]. In one of the first urinary proteomics studies, Mosley and colleagues utilized the surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SLEDI-TOF MS) technology and identified proteins with masses of 3340 and 3980 that best distinguished active from inactive lupus nephritis [<xref ref-type="bibr" rid="bibr122-1759720X13485503">Mosley <italic>et al.</italic> 2006</xref>]. Further analysis with serial urine samples of six patients with biopsy-confirmed lupus nephritis showed that these proteins could predict renal flares and remission earlier than conventional markers for nephritis. Subsequently, Suzuki and colleagues used a similar technique to investigate the urinary protein profile (‘signature’) in pediatric patients with lupus nephritis [<xref ref-type="bibr" rid="bibr163-1759720X13485503">Suzuki <italic>et al.</italic> 2007</xref>]. They identified 8 candidate peptides/proteins with molecular masses from 2700 to 133,000, including TF, AGP, CP, and L-PGDS. The peak intensities of these proteins were significantly stronger in patients with nephritis than in patients without nephritis and healthy controls. Moreover, these proteins significantly correlated with renal disease activity.</p>
<p>In a subsequent validation study, these investigators measured the concentrations of urinary TF, AGP, CP, and L-PGDS in serial samples from 98 pediatric SLE patients and 30 patients with juvenile idiopathic arthritis [<xref ref-type="bibr" rid="bibr164-1759720X13485503">Suzuki <italic>et al.</italic> 2009</xref>]. All four urinary proteins were present at significantly higher concentrations in SLE patients with active nephritis, compared to those with inactive nephritis or juvenile idiopathic arthritis. By analyzing the AUC, these urinary proteins performed better than traditional renal markers in identifying the presence of active nephritis. Furthermore, prospective analysis showed that significant increases of urinary TF, L-PGDS, and AGP, occurred as early as 3 months before clinical worsening of lupus nephritis. This latter result suggests that these urinary proteins, particularly TF, are sensitive biomarkers for changes in renal disease activity.</p>
<p>Most recently, Zhang and colleagues demonstrated the potential of a composite biomarker panel for lupus nephritis in adult SLE patients [<xref ref-type="bibr" rid="bibr193-1759720X13485503">Zhang <italic>et al.</italic> 2012</xref>]. In a study that included evaluation of 64 renal biopsies and simultaneous (or close-in-time) urine samples from 61 patients with lupus nephritis, they identified a composite panel including MCP-1 and serum creatinine that had sensitivity, specificity, positive predictive value, and negative predictive value of 100%, 81%, 67%, and 100%, respectively with only 14% of biopsies being misclassified.</p>
</sec>
</sec>
</sec>
<sec id="section27-1759720X13485503">
<title>Future prospects</title>
<p>Although many SLE biomarker reports have been published during the past decade, the majority of these have studied small numbers of patients and/or have been limited to cross-sectional observations. Owing to the heterogeneous nature of SLE with mounting evidence of the influence of geoepidemiology and epigenetics, it is perhaps not surprising that some of the biomarkers have yielded conflicting results in different studies or have failed to fulfill the early promising potential. The few longitudinal investigations that have been published have followed promising initial cross-sectional studies and more such long term prospective analyses are ongoing. Ultimately, validation of lupus biomarkers will require multicenter studies.</p>
<p>Until recently, the development of SLE biomarkers has primarily been focused on biomarkers that may assist in making a precise diagnosis or monitoring disease activity. Attempts have begun toward discovering biomarkers that might aid in predicting the onset of SLE in susceptible individuals and/or development of flares (systemic or organ-specific) in patients with established SLE, predicting disease outcome, and assessing the effectiveness of therapeutic interventions. These ‘next-generation’ SLE biomarkers will be particularly important because more sensitive and specific markers for the onset or flare of SLE disease activity may allow proactive institution of therapeutic and even preventive strategies so that the therapeutic efficacy can be enhanced while treatment-related side effects can be minimized. In the burgeoning era of biologic therapeutics, some of which have resulted from recent biomarker studies, a new class of pharmacodynamic biomarkers is needed to aid identification of patients who might respond favorably to a particular biologic, selection of the type and dose of biologics used, and evaluation of therapeutic efficacy. An illustrative example is sifalimumab and rontalizumab, anti-IFNα monoclonal antibodies under evaluation for the treatment of SLE, which were developed based on the seminal discovery of the IFN signature and related biomarkers. Specific and dose-dependent inhibition of type 1 IFN-inducible gene expression and improvement of skin lesions has been observed in the blood of treated SLE patients [<xref ref-type="bibr" rid="bibr110-1759720X13485503">Merrill <italic>et al.</italic> 2011</xref>]. It has been shown that, using a scoring or a metric system based on the expression of type 1 IFN-inducible genes, SLE patients could be divided into two distinct subpopulations [<xref ref-type="bibr" rid="bibr189-1759720X13485503">Yao <italic>et al.</italic> 2010</xref>]. This latter finding supports the possibility of using the IFN signature metric as predictive biomarkers to identify SLE patients who might respond more favorably to these biologics and as monitoring biomarkers to stratify patients’ responses.</p>
<p>Owing to the extreme complexity of the disease in its diagnosis, course and organ-specific manifestations as described above, we will most likely depend upon a panel of SLE biomarkers that will be used by physicians, scientists and industry for patient care, research, and drug discovery. This potentially daunting task will require collaborative efforts and novel approaches moving forward.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The authors’ studies mentioned in this article were supported by grants from the National Institutes of Health (RO1 HL074335 and RO1 AI077591), the Lupus Research Institute, and the Department of Defense.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors are co-inventors of patents related to the CB-CAP biomarkers that were mentioned in this article. Dr Ahearn and Dr Manzi are consultants of the Exagen Diagnostics, Vista, CA.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adhya</surname><given-names>Z.</given-names></name>
<name><surname>Borozdenkova</surname><given-names>S.</given-names></name>
<name><surname>Karim</surname><given-names>M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis</article-title>. <source>Nephrol Dial Transplant</source> <volume>26</volume>: <fpage>3273</fpage>–<lpage>3280</lpage>.</citation>
</ref>
<ref id="bibr2-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ahearn</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Kao</surname><given-names>A.</given-names></name>
<name><surname>Manzi</surname><given-names>S.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Biomarkers for systemic lupus erythematosus</article-title>. <source>Transl Res</source> <volume>159</volume>: <fpage>326</fpage>–<lpage>342</lpage>.</citation>
</ref>
<ref id="bibr3-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Akhter</surname><given-names>E.</given-names></name>
<name><surname>Burlingame</surname><given-names>R.</given-names></name>
<name><surname>Seaman</surname><given-names>A.</given-names></name>
<name><surname>Magder</surname><given-names>L.</given-names></name>
<name><surname>Petri</surname><given-names>M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers</article-title>. <source>Lupus</source> <volume>20</volume>: <fpage>1267</fpage>–<lpage>1274</lpage>.</citation>
</ref>
<ref id="bibr4-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Allan</surname><given-names>R.</given-names></name>
<name><surname>Zueva</surname><given-names>E.</given-names></name>
<name><surname>Cammas</surname><given-names>F.</given-names></name>
<name><surname>Schreiber</surname><given-names>H.</given-names></name>
<name><surname>Masson</surname><given-names>V.</given-names></name>
<name><surname>Belz</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>An epigenetic silencing pathway controlling T helper 2 cell lineage commitment</article-title>. <source>Nature</source> <volume>487</volume>: <fpage>249</fpage>–<lpage>253</lpage>.</citation>
</ref>
<ref id="bibr5-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Apostolidis</surname><given-names>S.</given-names></name>
<name><surname>Lieberman</surname><given-names>L.</given-names></name>
<name><surname>Kis-Toth</surname><given-names>K.</given-names></name>
<name><surname>Crispin</surname><given-names>J.</given-names></name>
<name><surname>Tsokos</surname><given-names>G.</given-names></name>
</person-group> (<year>2011</year>) <article-title>The dysregulation of cytokine networks in systemic lupus erythematosus</article-title>. <source>J Interferon Cytokine Res</source> <volume>31</volume>: <fpage>769</fpage>–<lpage>779</lpage>.</citation>
</ref>
<ref id="bibr6-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aringer</surname><given-names>M.</given-names></name>
<name><surname>Stummvoll</surname><given-names>G.</given-names></name>
<name><surname>Steiner</surname><given-names>G.</given-names></name>
<name><surname>Koller</surname><given-names>M.</given-names></name>
<name><surname>Steiner</surname><given-names>C.</given-names></name>
<name><surname>Hofler</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Serum interleukin-15 is elevated in systemic lupus erythematosus</article-title>. <source>Rheumatology (Oxford)</source> <volume>40</volume>: <fpage>876</fpage>–<lpage>881</lpage>.</citation>
</ref>
<ref id="bibr7-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Awasthi</surname><given-names>A.</given-names></name>
<name><surname>Carrier</surname><given-names>Y.</given-names></name>
<name><surname>Peron</surname><given-names>J.</given-names></name>
<name><surname>Bettelli</surname><given-names>E.</given-names></name>
<name><surname>Kamanaka</surname><given-names>M.</given-names></name>
<name><surname>Flavell</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells</article-title>. <source>Nat Immunol</source> <volume>8</volume>: <fpage>1380</fpage>–<lpage>1389</lpage>.</citation>
</ref>
<ref id="bibr8-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baechler</surname><given-names>E.</given-names></name>
<name><surname>Batliwalla</surname><given-names>F.</given-names></name>
<name><surname>Karypis</surname><given-names>G.</given-names></name>
<name><surname>Gaffney</surname><given-names>P.</given-names></name>
<name><surname>Ortmann</surname><given-names>W.</given-names></name>
<name><surname>Espe</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>100</volume>: <fpage>2610</fpage>–<lpage>2615</lpage>.</citation>
</ref>
<ref id="bibr9-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baltimore</surname><given-names>D.</given-names></name>
<name><surname>Boldin</surname><given-names>M.</given-names></name>
<name><surname>O’Connell</surname><given-names>R.</given-names></name>
<name><surname>Rao</surname><given-names>D.</given-names></name>
<name><surname>Taganov</surname><given-names>K.</given-names></name>
</person-group> (<year>2008</year>) <article-title>MicroRNAs: new regulators of immune cell development and function</article-title>. <source>Nat Immunol</source> <volume>9</volume>: <fpage>839</fpage>–<lpage>845</lpage>.</citation>
</ref>
<ref id="bibr10-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bartel</surname><given-names>D.</given-names></name>
</person-group> (<year>2004</year>) <article-title>MicroRNAs: genomics, biogenesis, mechanism, and function</article-title>. <source>Cell</source> <volume>116</volume>: <fpage>281</fpage>–<lpage>297</lpage>.</citation>
</ref>
<ref id="bibr11-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Basu</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>A.</given-names></name>
<name><surname>Yarlagadda</surname><given-names>S.</given-names></name>
<name><surname>Gorelik</surname><given-names>G.</given-names></name>
<name><surname>Kaplan</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Stimulatory and inhibitory killer Ig-like receptor molecules are expressed and functional on lupus T cells</article-title>. <source>J Immunol</source> <volume>183</volume>: <fpage>3481</fpage>–<lpage>3487</lpage>.</citation>
</ref>
<ref id="bibr12-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Batal</surname><given-names>I.</given-names></name>
<name><surname>Liang</surname><given-names>K.</given-names></name>
<name><surname>Bastacky</surname><given-names>S.</given-names></name>
<name><surname>Kiss</surname><given-names>L.</given-names></name>
<name><surname>McHale</surname><given-names>T.</given-names></name>
<name><surname>Wilson</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study</article-title>. <source>Lupus</source> <volume>21</volume>: <fpage>13</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr13-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bauer</surname><given-names>J.</given-names></name>
<name><surname>Baechler</surname><given-names>E.</given-names></name>
<name><surname>Petri</surname><given-names>M.</given-names></name>
<name><surname>Batliwalla</surname><given-names>F.</given-names></name>
<name><surname>Crawford</surname><given-names>D.</given-names></name>
<name><surname>Ortmann</surname><given-names>W.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus</article-title>. <source>PLoS Med</source> <volume>3</volume>(<issue>12</issue>): <fpage>e491</fpage>.</citation>
</ref>
<ref id="bibr14-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bauer</surname><given-names>J.</given-names></name>
<name><surname>Petri</surname><given-names>M.</given-names></name>
<name><surname>Batliwalla</surname><given-names>F.</given-names></name>
<name><surname>Koeuth</surname><given-names>T.</given-names></name>
<name><surname>Wilson</surname><given-names>J.</given-names></name>
<name><surname>Slattery</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study</article-title>. <source>Arthritis Rheum</source> <volume>60</volume>: <fpage>3098</fpage>–<lpage>3107</lpage>.</citation>
</ref>
<ref id="bibr15-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Becker-Merok</surname><given-names>A.</given-names></name>
<name><surname>Nikolaisen</surname><given-names>C.</given-names></name>
<name><surname>Nossent</surname><given-names>H.</given-names></name>
</person-group> (<year>2006</year>) <article-title>B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time</article-title>. <source>Lupus</source> <volume>15</volume>: <fpage>570</fpage>–<lpage>576</lpage>.</citation>
</ref>
<ref id="bibr16-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bennett</surname><given-names>L.</given-names></name>
<name><surname>Palucka</surname><given-names>K.</given-names></name>
<name><surname>Arce</surname><given-names>E.</given-names></name>
<name><surname>Cantrell</surname><given-names>V.</given-names></name>
<name><surname>Borvak</surname><given-names>J.</given-names></name>
<name><surname>Banchereau</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Interferon and granulopoiesis signatures in systemic lupus erythematosus blood</article-title>. <source>J Exp Med</source> <volume>197</volume>: <fpage>711</fpage>–<lpage>723</lpage>.</citation>
</ref>
<ref id="bibr17-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Biesen</surname><given-names>R.</given-names></name>
<name><surname>Demir</surname><given-names>C.</given-names></name>
<name><surname>Barkhudarova</surname><given-names>F.</given-names></name>
<name><surname>Grun</surname><given-names>J.</given-names></name>
<name><surname>Steinbrich-Zollner</surname><given-names>M.</given-names></name>
<name><surname>Backhaus</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <volume>58</volume>: <fpage>1136</fpage>–<lpage>1145</lpage>.</citation>
</ref>
<ref id="bibr18-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bigler</surname><given-names>C.</given-names></name>
<name><surname>Lopez-Trascasa</surname><given-names>M.</given-names></name>
<name><surname>Potlukova</surname><given-names>E.</given-names></name>
<name><surname>Moll</surname><given-names>S.</given-names></name>
<name><surname>Danner</surname><given-names>D.</given-names></name>
<name><surname>Schaller</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Antinucleosome antibodies as a marker of active proliferative lupus nephritis</article-title>. <source>Am J Kidney Dis</source> <volume>51</volume>: <fpage>624</fpage>–<lpage>629</lpage>.</citation>
</ref>
<ref id="bibr19-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bird</surname><given-names>A.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Perceptions of epigenetics</article-title>. <source>Nature</source> <volume>447</volume>: <fpage>396</fpage>–<lpage>398</lpage>.</citation>
</ref>
<ref id="bibr20-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bolignano</surname><given-names>D.</given-names></name>
<name><surname>Donato</surname><given-names>V.</given-names></name>
<name><surname>Coppolino</surname><given-names>G.</given-names></name>
<name><surname>Campo</surname><given-names>S.</given-names></name>
<name><surname>Buemi</surname><given-names>A.</given-names></name>
<name><surname>Lacquaniti</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage</article-title>. <source>Am J Kidney Dis</source> <volume>52</volume>: <fpage>595</fpage>–<lpage>605</lpage>.</citation>
</ref>
<ref id="bibr21-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brunner</surname><given-names>H.</given-names></name>
<name><surname>Bennett</surname><given-names>M.</given-names></name>
<name><surname>Mina</surname><given-names>R.</given-names></name>
<name><surname>Suzuki</surname><given-names>M.</given-names></name>
<name><surname>Petri</surname><given-names>M.</given-names></name>
<name><surname>Kiani</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis</article-title>. <source>Arthritis Rheum</source> <volume>64</volume>: <fpage>2687</fpage>–<lpage>2697</lpage>.</citation>
</ref>
<ref id="bibr22-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brunner</surname><given-names>H.</given-names></name>
<name><surname>Mueller</surname><given-names>M.</given-names></name>
<name><surname>Rutherford</surname><given-names>C.</given-names></name>
<name><surname>Passo</surname><given-names>M.</given-names></name>
<name><surname>Witte</surname><given-names>D.</given-names></name>
<name><surname>Grom</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <volume>54</volume>: <fpage>2577</fpage>–<lpage>2584</lpage>.</citation>
</ref>
<ref id="bibr23-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bruns</surname><given-names>A.</given-names></name>
<name><surname>Blass</surname><given-names>S.</given-names></name>
<name><surname>Hausdorf</surname><given-names>G.</given-names></name>
<name><surname>Burmester</surname><given-names>G.</given-names></name>
<name><surname>Hiepe</surname><given-names>F.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <volume>43</volume>: <fpage>2307</fpage>–<lpage>2315</lpage>.</citation>
</ref>
<ref id="bibr24-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cameron</surname><given-names>J.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Lupus nephritis</article-title>. <source>J Am Soc Nephrol</source> <volume>10</volume>: <fpage>413</fpage>–<lpage>424</lpage>.</citation>
</ref>
<ref id="bibr25-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carthew</surname><given-names>R.W.</given-names></name>
<name><surname>Sontheimer</surname><given-names>E.J.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Origins and Mechanisms of miRNAs and siRNAs</article-title>. <source>Cell</source> <volume>136</volume>: <fpage>642</fpage>–<lpage>655</lpage>.</citation>
</ref>
<ref id="bibr26-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cervera</surname><given-names>R.</given-names></name>
<name><surname>Vinas</surname><given-names>O.</given-names></name>
<name><surname>Ramos-Casals</surname><given-names>M.</given-names></name>
<name><surname>Font</surname><given-names>J.</given-names></name>
<name><surname>Garcia-Carrasco</surname><given-names>M.</given-names></name>
<name><surname>Siso</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy</article-title>. <source>Ann Rheum Dis</source> <volume>62</volume>: <fpage>431</fpage>–<lpage>434</lpage>.</citation>
</ref>
<ref id="bibr27-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chabre</surname><given-names>H.</given-names></name>
<name><surname>Amoura</surname><given-names>Z.</given-names></name>
<name><surname>Piette</surname><given-names>J.</given-names></name>
<name><surname>Godeau</surname><given-names>P.</given-names></name>
<name><surname>Bach</surname><given-names>J.</given-names></name>
<name><surname>Koutouzov</surname><given-names>S.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <volume>38</volume>: <fpage>1485</fpage>–<lpage>1491</lpage>.</citation>
</ref>
<ref id="bibr28-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chan</surname><given-names>R.</given-names></name>
<name><surname>Lai</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>E.</given-names></name>
<name><surname>Tam</surname><given-names>L.</given-names></name>
<name><surname>Chow</surname><given-names>K.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis</article-title>. <source>Nephrol Dial Transplant</source> <volume>21</volume>: <fpage>1534</fpage>–<lpage>1540</lpage>.</citation>
</ref>
<ref id="bibr29-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cheema</surname><given-names>G.</given-names></name>
<name><surname>Roschke</surname><given-names>V.</given-names></name>
<name><surname>Hilbert</surname><given-names>D.</given-names></name>
<name><surname>Stohl</surname><given-names>W.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases</article-title>. <source>Arthritis Rheum</source> <volume>44</volume>: <fpage>1313</fpage>–<lpage>1319</lpage>.</citation>
</ref>
<ref id="bibr30-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>G.</given-names></name>
<name><surname>Wang</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Anti-C1q antibody is a valuable biological marker for prediction of renal pathological characteristics in lupus nephritis</article-title>. <source>Clin Rheumatol</source> <volume>31</volume>: <fpage>1323</fpage>–<lpage>1329</lpage>.</citation>
</ref>
<ref id="bibr31-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chun</surname><given-names>H.</given-names></name>
<name><surname>Chung</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>H.</given-names></name>
<name><surname>Yun</surname><given-names>J.</given-names></name>
<name><surname>Jeon</surname><given-names>J.</given-names></name>
<name><surname>Ye</surname><given-names>Y.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus</article-title>. <source>J Clin Immunol</source> <volume>27</volume>: <fpage>461</fpage>–<lpage>466</lpage>.</citation>
</ref>
<ref id="bibr32-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>D.</given-names></name>
<name><surname>Koopmans</surname><given-names>M.</given-names></name>
<name><surname>Kremer Hovinga</surname><given-names>I.</given-names></name>
<name><surname>Berger</surname><given-names>S.</given-names></name>
<name><surname>Roos van Groningen</surname><given-names>M.</given-names></name>
<name><surname>Steup-Beekman</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis</article-title>. <source>Arthritis Rheum</source> <volume>58</volume>: <fpage>2460</fpage>–<lpage>2469</lpage>.</citation>
</ref>
<ref id="bibr33-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cornacchia</surname><given-names>E.</given-names></name>
<name><surname>Golbus</surname><given-names>J.</given-names></name>
<name><surname>Maybaum</surname><given-names>J.</given-names></name>
<name><surname>Strahler</surname><given-names>J.</given-names></name>
<name><surname>Hanash</surname><given-names>S.</given-names></name>
<name><surname>Richardson</surname><given-names>B.</given-names></name>
</person-group> (<year>1988</year>) <article-title>Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity</article-title>. <source>J Immunol</source> <volume>140</volume>: <fpage>2197</fpage>–<lpage>2200</lpage>.</citation>
</ref>
<ref id="bibr34-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crispin</surname><given-names>J.</given-names></name>
<name><surname>Keenan</surname><given-names>B.</given-names></name>
<name><surname>Finnell</surname><given-names>M.</given-names></name>
<name><surname>Bermas</surname><given-names>B.</given-names></name>
<name><surname>Schur</surname><given-names>P.</given-names></name>
<name><surname>Massarotti</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2010a</year>) <article-title>Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity</article-title>. <source>Arthritis Rheum</source> <volume>62</volume>: <fpage>1431</fpage>–<lpage>1437</lpage>.</citation>
</ref>
<ref id="bibr35-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crispin</surname><given-names>J.</given-names></name>
<name><surname>Liossis</surname><given-names>S.</given-names></name>
<name><surname>Kis-Toth</surname><given-names>K.</given-names></name>
<name><surname>Lieberman</surname><given-names>L.</given-names></name>
<name><surname>Kyttaris</surname><given-names>V.</given-names></name>
<name><surname>Juang</surname><given-names>Y.</given-names></name><etal/>
</person-group>. (<year>2010b</year>) <article-title>Pathogenesis of human systemic lupus erythematosus: recent advances</article-title>. <source>Trends Mol Med</source> <volume>16</volume>(<issue>2</issue>): <fpage>47</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr36-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crispin</surname><given-names>J.</given-names></name>
<name><surname>Oukka</surname><given-names>M.</given-names></name>
<name><surname>Bayliss</surname><given-names>G.</given-names></name>
<name><surname>Cohen</surname><given-names>R.</given-names></name>
<name><surname>Van Beek</surname><given-names>C.</given-names></name>
<name><surname>Stillman</surname><given-names>I.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys</article-title>. <source>J Immunol</source> <volume>181</volume>: <fpage>8761</fpage>–<lpage>8766</lpage>.</citation>
</ref>
<ref id="bibr37-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crispin</surname><given-names>J.</given-names></name>
<name><surname>Tsokos</surname><given-names>G.</given-names></name>
</person-group> (<year>2010a</year>) <article-title>IL-17 in systemic lupus erythematosus</article-title>. <source>J Biomed Biotechnol</source> <volume>2010</volume>: <fpage>943254</fpage>.</citation>
</ref>
<ref id="bibr38-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crispin</surname><given-names>J.</given-names></name>
<name><surname>Tsokos</surname><given-names>G.</given-names></name>
</person-group> (<year>2010b</year>) <article-title>Interleukin-17-producing T cells in lupus</article-title>. <source>Curr Opin Rheumatol</source> <volume>22</volume>: <fpage>499</fpage>–<lpage>503</lpage>.</citation>
</ref>
<ref id="bibr39-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crow</surname><given-names>M.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Type I interferon in systemic lupus erythematosus</article-title>. <source>Curr Top Microbiol Immunol</source> <volume>316</volume>: <fpage>359</fpage>–<lpage>386</lpage>.</citation>
</ref>
<ref id="bibr40-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dai</surname><given-names>R.</given-names></name>
<name><surname>Ahmed</surname><given-names>S.</given-names></name>
</person-group> (<year>2011</year>) <article-title>MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases</article-title>. <source>Transl Res</source> <volume>157</volume>: <fpage>163</fpage>–<lpage>179</lpage>.</citation>
</ref>
<ref id="bibr41-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dai</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Tang</surname><given-names>M.</given-names></name>
<name><surname>Lv</surname><given-names>T.</given-names></name>
<name><surname>Hu</surname><given-names>C.</given-names></name>
<name><surname>Tan</surname><given-names>Y.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients</article-title>. <source>Lupus</source> <volume>16</volume>: <fpage>939</fpage>–<lpage>946</lpage>.</citation>
</ref>
<ref id="bibr42-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dai</surname><given-names>Y.</given-names></name>
<name><surname>Sui</surname><given-names>W.</given-names></name>
<name><surname>Lan</surname><given-names>H.</given-names></name>
<name><surname>Yan</surname><given-names>Q.</given-names></name>
<name><surname>Huang</surname><given-names>H.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
</person-group> (<year>2009a</year>) <article-title>Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients</article-title>. <source>Rheumatol Int</source> <volume>29</volume>: <fpage>749</fpage>–<lpage>754</lpage>.</citation>
</ref>
<ref id="bibr43-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dai</surname><given-names>Z.</given-names></name>
<name><surname>Turtle</surname><given-names>C.</given-names></name>
<name><surname>Booth</surname><given-names>G.</given-names></name>
<name><surname>Riddell</surname><given-names>S.</given-names></name>
<name><surname>Gooley</surname><given-names>T.</given-names></name>
<name><surname>Stevens</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2009b</year>) <article-title>Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus</article-title>. <source>J Exp Med</source> <volume>206</volume>: <fpage>793</fpage>–<lpage>805</lpage>.</citation>
</ref>
<ref id="bibr44-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>L.</given-names></name>
<name><surname>Hutcheson</surname><given-names>J.</given-names></name>
<name><surname>Mohan</surname><given-names>C.</given-names></name>
</person-group> (<year>2011</year>) <article-title>The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus</article-title>. <source>J Interferon Cytokine Res</source> <volume>31</volume>: <fpage>781</fpage>–<lpage>789</lpage>.</citation>
</ref>
<ref id="bibr45-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deapen</surname><given-names>D.</given-names></name>
<name><surname>Escalante</surname><given-names>A.</given-names></name>
<name><surname>Weinrib</surname><given-names>L.</given-names></name>
<name><surname>Horwitz</surname><given-names>D.</given-names></name>
<name><surname>Bachman</surname><given-names>B.</given-names></name>
<name><surname>Roy-Burman</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>1992</year>) <article-title>A revised estimate of twin concordance in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <volume>35</volume>: <fpage>311</fpage>–<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr46-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deng</surname><given-names>G.</given-names></name>
<name><surname>Tsokos</surname><given-names>G.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation</article-title>. <source>J Immunol</source> <volume>181</volume>: <fpage>4019</fpage>–<lpage>4026</lpage>.</citation>
</ref>
<ref id="bibr47-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deng</surname><given-names>Y.</given-names></name>
<name><surname>Tsao</surname><given-names>B.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Genetic susceptibility to systemic lupus erythematosus in the genomic era</article-title>. <source>Nat Rev Rheumatol</source> <volume>6</volume>: <fpage>683</fpage>–<lpage>692</lpage>.</citation>
</ref>
<ref id="bibr48-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dong</surname><given-names>L.</given-names></name>
<name><surname>Hu</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>F.</given-names></name>
<name><surname>Lei</surname><given-names>X.</given-names></name>
<name><surname>Tu</surname><given-names>W.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Increased expression of ganglioside GM1 in peripheral CD4+ T cells correlates soluble form of CD30 in systemic lupus erythematosus patients</article-title>. <source>J Biomed Biotechnol</source> <volume>2010</volume>: <fpage>569053</fpage>.</citation>
</ref>
<ref id="bibr49-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Doreau</surname><given-names>A.</given-names></name>
<name><surname>Belot</surname><given-names>A.</given-names></name>
<name><surname>Bastid</surname><given-names>J.</given-names></name>
<name><surname>Riche</surname><given-names>B.</given-names></name>
<name><surname>Trescol-Biemont</surname><given-names>M.</given-names></name>
<name><surname>Ranchin</surname><given-names>B.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus</article-title>. <source>Nat Immunol</source> <volume>10</volume>: <fpage>778</fpage>–<lpage>785</lpage>.</citation>
</ref>
<ref id="bibr50-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Elkon</surname><given-names>K.</given-names></name>
<name><surname>Wiedeman</surname><given-names>A.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Type I IFN system in the development and manifestations of SLE</article-title>. <source>Curr Opin Rheumatol</source> <volume>24</volume>: <fpage>499</fpage>–<lpage>505</lpage>.</citation>
</ref>
<ref id="bibr51-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ettinger</surname><given-names>R.</given-names></name>
<name><surname>Kuchen</surname><given-names>S.</given-names></name>
<name><surname>Lipsky</surname><given-names>P.</given-names></name>
</person-group> (<year>2008</year>) <article-title>The role of IL-21 in regulating B-cell function in health and disease</article-title>. <source>Immunol Rev</source> <volume>223</volume>: <fpage>60</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr52-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fabian</surname><given-names>M.</given-names></name>
<name><surname>Sonenberg</surname><given-names>N.</given-names></name>
<name><surname>Filipowicz</surname><given-names>W.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Regulation of mRNA translation and stability by microRNAs</article-title>. <source>Annu Rev Biochem</source> <volume>79</volume>: <fpage>351</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr53-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Feng</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>H.</given-names></name>
<name><surname>Grossman</surname><given-names>J.</given-names></name>
<name><surname>Hanvivadhanakul</surname><given-names>P.</given-names></name>
<name><surname>FitzGerald</surname><given-names>J.</given-names></name>
<name><surname>Park</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <volume>54</volume>: <fpage>2951</fpage>–<lpage>2962</lpage>.</citation>
</ref>
<ref id="bibr54-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fields</surname><given-names>P.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Flavell</surname><given-names>R.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Cutting edge: changes in histone acetylation at the IL-4 and IFN-gamma loci accompany Th1/Th2 differentiation</article-title>. <source>J Immunol</source> <volume>169</volume>: <fpage>647</fpage>–<lpage>650</lpage>.</citation>
</ref>
<ref id="bibr55-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Flesher</surname><given-names>D.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Behrens</surname><given-names>T.</given-names></name>
<name><surname>Graham</surname><given-names>R.</given-names></name>
<name><surname>Criswell</surname><given-names>L.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Recent advances in the genetics of systemic lupus erythematosus</article-title>. <source>Expert Rev Clin Immunol</source> <volume>6</volume>: <fpage>461</fpage>–<lpage>479</lpage>.</citation>
</ref>
<ref id="bibr56-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fraga</surname><given-names>M.</given-names></name>
<name><surname>Ballestar</surname><given-names>E.</given-names></name>
<name><surname>Paz</surname><given-names>M.</given-names></name>
<name><surname>Ropero</surname><given-names>S.</given-names></name>
<name><surname>Setien</surname><given-names>F.</given-names></name>
<name><surname>Ballestar</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Epigenetic differences arise during the lifetime of monozygotic twins</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>102</volume>: <fpage>10604</fpage>–<lpage>10609</lpage>.</citation>
</ref>
<ref id="bibr57-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gabay</surname><given-names>C.</given-names></name>
<name><surname>McInnes</surname><given-names>I.</given-names></name>
</person-group> (<year>2009</year>) <article-title>The biological and clinical importance of the ‘new generation’ cytokines in rheumatic diseases</article-title>. <source>Arthritis Res Ther</source> <volume>11</volume>: <fpage>230</fpage>.</citation>
</ref>
<ref id="bibr58-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gao</surname><given-names>H.</given-names></name>
<name><surname>Campbell</surname><given-names>S.</given-names></name>
<name><surname>Burkly</surname><given-names>L.</given-names></name>
<name><surname>Jakubowski</surname><given-names>A.</given-names></name>
<name><surname>Jarchum</surname><given-names>I.</given-names></name>
<name><surname>Banas</surname><given-names>B.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells</article-title>. <source>Cytokine</source> <volume>46</volume>: <fpage>24</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr59-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gomez-Puerta</surname><given-names>J.</given-names></name>
<name><surname>Burlingame</surname><given-names>R.</given-names></name>
<name><surname>Cervera</surname><given-names>R.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value</article-title>. <source>Autoimmun Rev</source> <volume>7</volume>: <fpage>606</fpage>–<lpage>611</lpage>.</citation>
</ref>
<ref id="bibr60-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grootscholten</surname><given-names>C.</given-names></name>
<name><surname>Dieker</surname><given-names>J.</given-names></name>
<name><surname>McGrath</surname><given-names>F.</given-names></name>
<name><surname>Roos</surname><given-names>A.</given-names></name>
<name><surname>Derksen</surname><given-names>R.</given-names></name>
<name><surname>van der Vlag</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone</article-title>. <source>Ann Rheum Dis</source> <volume>66</volume>: <fpage>693</fpage>–<lpage>696</lpage>.</citation>
</ref>
<ref id="bibr61-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gutierrez-Adrianzen</surname><given-names>O.</given-names></name>
<name><surname>Koutouzov</surname><given-names>S.</given-names></name>
<name><surname>Mota</surname><given-names>R.</given-names></name>
<name><surname>das Chagas Medeiros</surname><given-names>M.</given-names></name>
<name><surname>Bach</surname><given-names>J.</given-names></name>
<name><surname>de Holanda Campos</surname><given-names>H.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies</article-title>. <source>J Rheumatol</source> <volume>33</volume>: <fpage>1538</fpage>–<lpage>1544</lpage>.</citation>
</ref>
<ref id="bibr62-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harder</surname><given-names>T.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Lipid raft domains and protein networks in T-cell receptor signal transduction</article-title>. <source>Curr Opin Immunol</source> <volume>16</volume>: <fpage>353</fpage>–<lpage>359</lpage>.</citation>
</ref>
<ref id="bibr63-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harigai</surname><given-names>M.</given-names></name>
<name><surname>Kawamoto</surname><given-names>M.</given-names></name>
<name><surname>Hara</surname><given-names>M.</given-names></name>
<name><surname>Kubota</surname><given-names>T.</given-names></name>
<name><surname>Kamatani</surname><given-names>N.</given-names></name>
<name><surname>Miyasaka</surname><given-names>N.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B</article-title>. <source>J Immunol</source> <volume>181</volume>: <fpage>2211</fpage>–<lpage>2219</lpage>.</citation>
</ref>
<ref id="bibr64-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herbst</surname><given-names>R.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Jallal</surname><given-names>B.</given-names></name>
<name><surname>Yao</surname><given-names>Y.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Biomarkers for systemic lupus erythematosus</article-title>. <source>Int J Rheum Dis</source> <volume>15</volume>: <fpage>433</fpage>–<lpage>444</lpage>.</citation>
</ref>
<ref id="bibr65-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hinze</surname><given-names>C.</given-names></name>
<name><surname>Suzuki</surname><given-names>M.</given-names></name>
<name><surname>Klein-Gitelman</surname><given-names>M.</given-names></name>
<name><surname>Passo</surname><given-names>M.</given-names></name>
<name><surname>Olson</surname><given-names>J.</given-names></name>
<name><surname>Singer</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity</article-title>. <source>Arthritis Rheum</source> <volume>60</volume>: <fpage>2772</fpage>–<lpage>2781</lpage>.</citation>
</ref>
<ref id="bibr66-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoffman</surname><given-names>R.</given-names></name>
</person-group> (<year>2004</year>) <article-title>T cells in the pathogenesis of systemic lupus erythematosus</article-title>. <source>Clin Immunol</source> <volume>113</volume>: <fpage>4</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr67-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hooks</surname><given-names>J.</given-names></name>
<name><surname>Moutsopoulos</surname><given-names>H.</given-names></name>
<name><surname>Geis</surname><given-names>S.</given-names></name>
<name><surname>Stahl</surname><given-names>N.</given-names></name>
<name><surname>Decker</surname><given-names>J.</given-names></name>
<name><surname>Notkins</surname><given-names>A.</given-names></name>
</person-group> (<year>1979</year>) <article-title>Immune interferon in the circulation of patients with autoimmune disease</article-title>. <source>N Engl J Med</source> <volume>301</volume>: <fpage>5</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr68-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Horak</surname><given-names>P.</given-names></name>
<name><surname>Hermanova</surname><given-names>Z.</given-names></name>
<name><surname>Zadrazil</surname><given-names>J.</given-names></name>
<name><surname>Ciferska</surname><given-names>H.</given-names></name>
<name><surname>Ordeltova</surname><given-names>M.</given-names></name>
<name><surname>Kusa</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>C1q complement component and -antibodies reflect SLE activity and kidney involvement</article-title>. <source>Clin Rheumatol</source> <volume>25</volume>: <fpage>532</fpage>–<lpage>536</lpage>.</citation>
</ref>
<ref id="bibr69-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Horvath</surname><given-names>L.</given-names></name>
<name><surname>Czirjak</surname><given-names>L.</given-names></name>
<name><surname>Fekete</surname><given-names>B.</given-names></name>
<name><surname>Jakab</surname><given-names>L.</given-names></name>
<name><surname>Pozsonyi</surname><given-names>T.</given-names></name>
<name><surname>Kalabay</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>High levels of antibodies against Clq are associated with disease activity and nephritis but not with other organ manifestations in SLE patients</article-title>. <source>Clin Exp Rheumatol</source> <volume>19</volume>: <fpage>667</fpage>–<lpage>672</lpage>.</citation>
</ref>
<ref id="bibr70-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hu</surname><given-names>N.</given-names></name>
<name><surname>Qiu</surname><given-names>X.</given-names></name>
<name><surname>Luo</surname><given-names>Y.</given-names></name>
<name><surname>Yuan</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Lei</surname><given-names>W.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Abnormal histone modification patterns in lupus CD4+ T cells</article-title>. <source>J Rheumatol</source> <volume>35</volume>: <fpage>804</fpage>–<lpage>810</lpage>.</citation>
</ref>
<ref id="bibr71-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hughes</surname><given-names>T.</given-names></name>
<name><surname>Sawalha</surname><given-names>A.</given-names></name>
</person-group> (<year>2011</year>) <article-title>The role of epigenetic variation in the pathogenesis of systemic lupus erythematosus</article-title>. <source>Arthritis Res Ther</source> <volume>13</volume>: <fpage>245</fpage>.</citation>
</ref>
<ref id="bibr72-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hughes</surname><given-names>T.</given-names></name>
<name><surname>Webb</surname><given-names>R.</given-names></name>
<name><surname>Fei</surname><given-names>Y.</given-names></name>
<name><surname>Wren</surname><given-names>J.</given-names></name>
<name><surname>Sawalha</surname><given-names>A.</given-names></name>
</person-group> (<year>2010</year>) <article-title>DNA methylome in human CD4+ T cells identifies transcriptionally repressive and non-repressive methylation peaks</article-title>. <source>Genes Immun</source> <volume>11</volume>: <fpage>554</fpage>–<lpage>560</lpage>.</citation>
</ref>
<ref id="bibr73-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hung</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Lan</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Antinucleosome antibodies as a potential biomarker for the evaluation of renal pathological activity in patients with proliferative lupus nephritis</article-title>. <source>Lupus</source> <volume>20</volume>: <fpage>1404</fpage>–<lpage>1410</lpage>.</citation>
</ref>
<ref id="bibr74-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Illei</surname><given-names>G.</given-names></name>
<name><surname>Tackey</surname><given-names>E.</given-names></name>
<name><surname>Lapteva</surname><given-names>L.</given-names></name>
<name><surname>Lipsky</surname><given-names>P.</given-names></name>
</person-group> (<year>2004a</year>) <article-title>Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability</article-title>. <source>Arthritis Rheum</source> <volume>50</volume>: <fpage>1709</fpage>–<lpage>1720</lpage>.</citation>
</ref>
<ref id="bibr75-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Illei</surname><given-names>G.</given-names></name>
<name><surname>Tackey</surname><given-names>E.</given-names></name>
<name><surname>Lapteva</surname><given-names>L.</given-names></name>
<name><surname>Lipsky</surname><given-names>P.</given-names></name>
</person-group> (<year>2004b</year>) <article-title>Biomarkers in systemic lupus erythematosus: II. Markers of disease activity</article-title>. <source>Arthritis Rheum</source> <volume>50</volume>: <fpage>2048</fpage>–<lpage>2065</lpage>.</citation>
</ref>
<ref id="bibr76-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Javierre</surname><given-names>B.</given-names></name>
<name><surname>Fernandez</surname><given-names>A.</given-names></name>
<name><surname>Richter</surname><given-names>J.</given-names></name>
<name><surname>Al-Shahrour</surname><given-names>F.</given-names></name>
<name><surname>Martin-Subero</surname><given-names>J.</given-names></name>
<name><surname>Rodriguez-Ubreva</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus</article-title>. <source>Genome Res</source> <volume>20</volume>: <fpage>170</fpage>–<lpage>179</lpage>.</citation>
</ref>
<ref id="bibr77-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jeffries</surname><given-names>M.</given-names></name>
<name><surname>Dozmorov</surname><given-names>M.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
<name><surname>Merrill</surname><given-names>J.</given-names></name>
<name><surname>Wren</surname><given-names>J.</given-names></name>
<name><surname>Sawalha</surname><given-names>A.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus</article-title>. <source>Epigenetics</source> <volume>6</volume>: <fpage>593</fpage>–<lpage>601</lpage>.</citation>
</ref>
<ref id="bibr78-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jeffries</surname><given-names>M.</given-names></name>
<name><surname>Sawalha</surname><given-names>A.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents</article-title>. <source>Int J Clin Rheumatol</source> <volume>6</volume>: <fpage>423</fpage>–<lpage>439</lpage>.</citation>
</ref>
<ref id="bibr79-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Juang</surname><given-names>Y.</given-names></name>
<name><surname>Peoples</surname><given-names>C.</given-names></name>
<name><surname>Kafri</surname><given-names>R.</given-names></name>
<name><surname>Kyttaris</surname><given-names>V.</given-names></name>
<name><surname>Sunahori</surname><given-names>K.</given-names></name>
<name><surname>Kis-Toth</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>A systemic lupus erythematosus gene expression array in disease diagnosis and classification: a preliminary report</article-title>. <source>Lupus</source> <volume>20</volume>: <fpage>243</fpage>–<lpage>249</lpage>.</citation>
</ref>
<ref id="bibr80-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jury</surname><given-names>E.</given-names></name>
<name><surname>Flores-Borja</surname><given-names>F.</given-names></name>
<name><surname>Kabouridis</surname><given-names>P.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Lipid rafts in T cell signalling and disease</article-title>. <source>Semin Cell Dev Biol</source> <volume>18</volume>: <fpage>608</fpage>–<lpage>615</lpage>.</citation>
</ref>
<ref id="bibr81-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jury</surname><given-names>E.</given-names></name>
<name><surname>Isenberg</surname><given-names>D.</given-names></name>
<name><surname>Mauri</surname><given-names>C.</given-names></name>
<name><surname>Ehrenstein</surname><given-names>M.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus</article-title>. <source>J Immunol</source> <volume>177</volume>: <fpage>7416</fpage>–<lpage>7422</lpage>.</citation>
</ref>
<ref id="bibr82-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jury</surname><given-names>E.</given-names></name>
<name><surname>Kabouridis</surname><given-names>P.</given-names></name>
<name><surname>Flores-Borja</surname><given-names>F.</given-names></name>
<name><surname>Mageed</surname><given-names>R.</given-names></name>
<name><surname>Isenberg</surname><given-names>D.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus</article-title>. <source>J Clin Invest</source> <volume>113</volume>: <fpage>1176</fpage>–<lpage>1187</lpage>.</citation>
</ref>
<ref id="bibr83-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kabouridis</surname><given-names>P.</given-names></name>
<name><surname>Jury</surname><given-names>E.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Lipid rafts and T-lymphocyte function: implications for autoimmunity</article-title>. <source>FEBS Lett</source> <volume>582</volume>: <fpage>3711</fpage>–<lpage>3718</lpage>.</citation>
</ref>
<ref id="bibr84-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kalunian</surname><given-names>K.</given-names></name>
<name><surname>Chatham</surname><given-names>W.</given-names></name>
<name><surname>Massarotti</surname><given-names>E.</given-names></name>
<name><surname>Reyes-Thomas</surname><given-names>J.</given-names></name>
<name><surname>Harris</surname><given-names>C.</given-names></name>
<name><surname>Furie</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <volume>64</volume>: <fpage>4040</fpage>–<lpage>4047</lpage>.</citation>
</ref>
<ref id="bibr85-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaplan</surname><given-names>M.</given-names></name>
<name><surname>Lu</surname><given-names>Q.</given-names></name>
<name><surname>Wu</surname><given-names>A.</given-names></name>
<name><surname>Attwood</surname><given-names>J.</given-names></name>
<name><surname>Richardson</surname><given-names>B.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T cells</article-title>. <source>J Immunol</source> <volume>172</volume>: <fpage>3652</fpage>–<lpage>3661</lpage>.</citation>
</ref>
<ref id="bibr86-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karageorgas</surname><given-names>T.</given-names></name>
<name><surname>Tseronis</surname><given-names>D.</given-names></name>
<name><surname>Mavragani</surname><given-names>C.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes</article-title>. <source>J Biomed Biotechnol</source> <volume>2011</volume>: <fpage>273907</fpage>.</citation>
</ref>
<ref id="bibr87-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kiani</surname><given-names>A.</given-names></name>
<name><surname>Johnson</surname><given-names>K.</given-names></name>
<name><surname>Chen</surname><given-names>C.</given-names></name>
<name><surname>Diehl</surname><given-names>E.</given-names></name>
<name><surname>Hu</surname><given-names>H.</given-names></name>
<name><surname>Vasudevan</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis</article-title>. <source>J Rheumatol</source> <volume>36</volume>: <fpage>2224</fpage>–<lpage>2230</lpage>.</citation>
</ref>
<ref id="bibr88-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kiani</surname><given-names>A.</given-names></name>
<name><surname>Wu</surname><given-names>T.</given-names></name>
<name><surname>Fang</surname><given-names>H.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
<name><surname>Ahn</surname><given-names>C.</given-names></name>
<name><surname>Magder</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis</article-title>. <source>J Rheumatol</source> <volume>39</volume>: <fpage>1231</fpage>–<lpage>1237</lpage>.</citation>
</ref>
<ref id="bibr89-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kirou</surname><given-names>K.</given-names></name>
<name><surname>Lee</surname><given-names>C.</given-names></name>
<name><surname>George</surname><given-names>S.</given-names></name>
<name><surname>Louca</surname><given-names>K.</given-names></name>
<name><surname>Peterson</surname><given-names>M.</given-names></name>
<name><surname>Crow</surname><given-names>M.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease</article-title>. <source>Arthritis Rheum</source> <volume>52</volume>: <fpage>1491</fpage>–<lpage>1503</lpage>.</citation>
</ref>
<ref id="bibr90-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Korn</surname><given-names>T.</given-names></name>
<name><surname>Bettelli</surname><given-names>E.</given-names></name>
<name><surname>Oukka</surname><given-names>M.</given-names></name>
<name><surname>Kuchroo</surname><given-names>V.</given-names></name>
</person-group> (<year>2009</year>) <article-title>IL-17 and Th17 Cells</article-title>. <source>Annu Rev Immunol</source> <volume>27</volume>: <fpage>485</fpage>–<lpage>517</lpage>.</citation>
</ref>
<ref id="bibr91-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koutouzov</surname><given-names>S.</given-names></name>
<name><surname>Jeronimo</surname><given-names>A.</given-names></name>
<name><surname>Campos</surname><given-names>H.</given-names></name>
<name><surname>Amoura</surname><given-names>Z.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Nucleosomes in the pathogenesis of systemic lupus erythematosus</article-title>. <source>Rheum Dis Clin North Am</source> <volume>30</volume>: <fpage>529</fpage>–<lpage>558</lpage>.</citation>
</ref>
<ref id="bibr92-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krishnan</surname><given-names>S.</given-names></name>
<name><surname>Nambiar</surname><given-names>M.</given-names></name>
<name><surname>Warke</surname><given-names>V.</given-names></name>
<name><surname>Fisher</surname><given-names>C.</given-names></name>
<name><surname>Mitchell</surname><given-names>J.</given-names></name>
<name><surname>Delaney</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus</article-title>. <source>J Immunol</source> <volume>172</volume>: <fpage>7821</fpage>–<lpage>7831</lpage>.</citation>
</ref>
<ref id="bibr93-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Landolt-Marticorena</surname><given-names>C.</given-names></name>
<name><surname>Bonventi</surname><given-names>G.</given-names></name>
<name><surname>Lubovich</surname><given-names>A.</given-names></name>
<name><surname>Ferguson</surname><given-names>C.</given-names></name>
<name><surname>Unnithan</surname><given-names>T.</given-names></name>
<name><surname>Su</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus</article-title>. <source>Ann Rheum Dis</source> <volume>68</volume>: <fpage>1440</fpage>–<lpage>1446</lpage>.</citation>
</ref>
<ref id="bibr94-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laurent</surname><given-names>L.</given-names></name>
<name><surname>Wong</surname><given-names>E.</given-names></name>
<name><surname>Li</surname><given-names>G.</given-names></name>
<name><surname>Huynh</surname><given-names>T.</given-names></name>
<name><surname>Tsirigos</surname><given-names>A.</given-names></name>
<name><surname>Ong</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Dynamic changes in the human methylome during differentiation</article-title>. <source>Genome Res</source> <volume>20</volume>: <fpage>320</fpage>–<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr95-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>G.</given-names></name>
<name><surname>Zhu</surname><given-names>Q.</given-names></name>
<name><surname>Tao</surname><given-names>J.</given-names></name>
<name><surname>Pan</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Low level of serum interleukin 27 in patients with systemic lupus erythematosus</article-title>. <source>J Investig Med</source> <volume>58</volume>: <fpage>737</fpage>–<lpage>739</lpage>.</citation>
</ref>
<ref id="bibr96-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lin</surname><given-names>S.</given-names></name>
<name><surname>Hsieh</surname><given-names>S.</given-names></name>
<name><surname>Lin</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>C.</given-names></name>
<name><surname>Tsai</surname><given-names>M.</given-names></name>
<name><surname>Lai</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>A whole genome methylation analysis of systemic lupus erythematosus: hypomethylation of the IL10 and IL1R2 promoters is associated with disease activity</article-title>. <source>Genes Immun</source> <volume>13</volume>: <fpage>214</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr97-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Manzi</surname><given-names>S.</given-names></name>
<name><surname>Kao</surname><given-names>A.</given-names></name>
<name><surname>Navratil</surname><given-names>J.</given-names></name>
<name><surname>Ahearn</surname><given-names>J.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Cell-bound complement biomarkers for systemic lupus erythematosus: from benchtop to bedside</article-title>. <source>Rheum Dis Clin North Am</source> <volume>36</volume>: <fpage>161</fpage>–<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr98-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Kuick</surname><given-names>R.</given-names></name>
<name><surname>Hanash</surname><given-names>S.</given-names></name>
<name><surname>Richardson</surname><given-names>B.</given-names></name>
</person-group> (<year>2009</year>) <article-title>DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors</article-title>. <source>Clin Immunol</source> <volume>130</volume>: <fpage>213</fpage>–<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr99-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lu</surname><given-names>Q.</given-names></name>
<name><surname>Kaplan</surname><given-names>M.</given-names></name>
<name><surname>Ray</surname><given-names>D.</given-names></name>
<name><surname>Zacharek</surname><given-names>S.</given-names></name>
<name><surname>Gutsch</surname><given-names>D.</given-names></name>
<name><surname>Richardson</surname><given-names>B.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <volume>46</volume>: <fpage>1282</fpage>–<lpage>1291</lpage>.</citation>
</ref>
<ref id="bibr100-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lu</surname><given-names>Q.</given-names></name>
<name><surname>Wu</surname><given-names>A.</given-names></name>
<name><surname>Richardson</surname><given-names>B.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs</article-title>. <source>J Immunol</source> <volume>174</volume>: <fpage>6212</fpage>–<lpage>6219</lpage>.</citation>
</ref>
<ref id="bibr101-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lu</surname><given-names>Q.</given-names></name>
<name><surname>Wu</surname><given-names>A.</given-names></name>
<name><surname>Tesmer</surname><given-names>L.</given-names></name>
<name><surname>Ray</surname><given-names>D.</given-names></name>
<name><surname>Yousif</surname><given-names>N.</given-names></name>
<name><surname>Richardson</surname><given-names>B.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Demethylation of CD40LG on the inactive X in T cells from women with lupus</article-title>. <source>J Immunol</source> <volume>179</volume>: <fpage>6352</fpage>–<lpage>6358</lpage>.</citation>
</ref>
<ref id="bibr102-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luger</surname><given-names>K.</given-names></name>
<name><surname>Dechassa</surname><given-names>M.</given-names></name>
<name><surname>Tremethick</surname><given-names>D.</given-names></name>
</person-group> (<year>2012</year>) <article-title>New insights into nucleosome and chromatin structure: an ordered state or a disordered affair?</article-title> <source>Nat Rev Mol Cell Biol</source> <volume>13</volume>: <fpage>436</fpage>–<lpage>447</lpage>.</citation>
</ref>
<ref id="bibr103-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mackay</surname><given-names>F.</given-names></name>
<name><surname>Schneider</surname><given-names>P.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Cracking the BAFF code</article-title>. <source>Nat Rev Immunol</source> <volume>9</volume>: <fpage>491</fpage>–<lpage>502</lpage>.</citation>
</ref>
<ref id="bibr104-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manderson</surname><given-names>A.</given-names></name>
<name><surname>Botto</surname><given-names>M.</given-names></name>
<name><surname>Walport</surname><given-names>M.</given-names></name>
</person-group> (<year>2004</year>) <article-title>The role of complement in the development of systemic lupus erythematosus</article-title>. <source>Annu Rev Immunol</source> <volume>22</volume>: <fpage>431</fpage>–<lpage>456</lpage>.</citation>
</ref>
<ref id="bibr105-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manolio</surname><given-names>T.</given-names></name>
<name><surname>Collins</surname><given-names>F.</given-names></name>
<name><surname>Cox</surname><given-names>N.</given-names></name>
<name><surname>Goldstein</surname><given-names>D.</given-names></name>
<name><surname>Hindorff</surname><given-names>L.</given-names></name>
<name><surname>Hunter</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Finding the missing heritability of complex diseases</article-title>. <source>Nature</source> <volume>461</volume>: <fpage>747</fpage>–<lpage>753</lpage>.</citation>
</ref>
<ref id="bibr106-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manson</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>A.</given-names></name>
<name><surname>Rogers</surname><given-names>P.</given-names></name>
<name><surname>Mason</surname><given-names>L.</given-names></name>
<name><surname>Berden</surname><given-names>J.</given-names></name>
<name><surname>van der Vlag</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study</article-title>. <source>Arthritis Res Ther</source> <volume>11</volume>(<issue>5</issue>): <fpage>R154</fpage>.</citation>
</ref>
<ref id="bibr107-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marto</surname><given-names>N.</given-names></name>
<name><surname>Bertolaccini</surname><given-names>M.</given-names></name>
<name><surname>Calabuig</surname><given-names>E.</given-names></name>
<name><surname>Hughes</surname><given-names>G.</given-names></name>
<name><surname>Khamashta</surname><given-names>M.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus</article-title>. <source>Ann Rheum Dis</source> <volume>64</volume>: <fpage>444</fpage>–<lpage>448</lpage>.</citation>
</ref>
<ref id="bibr108-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matrat</surname><given-names>A.</given-names></name>
<name><surname>Veysseyre-Balter</surname><given-names>C.</given-names></name>
<name><surname>Trolliet</surname><given-names>P.</given-names></name>
<name><surname>Villar</surname><given-names>E.</given-names></name>
<name><surname>Dijoud</surname><given-names>F.</given-names></name>
<name><surname>Bienvenu</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares</article-title>. <source>Lupus</source> <volume>20</volume>: <fpage>28</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr109-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McKinney</surname><given-names>E.</given-names></name>
<name><surname>Lyons</surname><given-names>P.</given-names></name>
<name><surname>Carr</surname><given-names>E.</given-names></name>
<name><surname>Hollis</surname><given-names>J.</given-names></name>
<name><surname>Jayne</surname><given-names>D.</given-names></name>
<name><surname>Willcocks</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>A CD8+ T cell transcription signature predicts prognosis in autoimmune disease</article-title>. <source>Nat Med</source> <volume>16</volume>: <fpage>586</fpage>–<lpage>591</lpage>, 581p following 591.</citation>
</ref>
<ref id="bibr110-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Merrill</surname><given-names>J.</given-names></name>
<name><surname>Wallace</surname><given-names>D.</given-names></name>
<name><surname>Petri</surname><given-names>M.</given-names></name>
<name><surname>Kirou</surname><given-names>K.</given-names></name>
<name><surname>Yao</surname><given-names>Y.</given-names></name>
<name><surname>White</surname><given-names>W.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study</article-title>. <source>Ann Rheum Dis</source> <volume>70</volume>: <fpage>1905</fpage>–<lpage>1913</lpage>.</citation>
</ref>
<ref id="bibr111-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meyer</surname><given-names>O.</given-names></name>
<name><surname>Nicaise-Roland</surname><given-names>P.</given-names></name>
<name><surname>Cadoudal</surname><given-names>N.</given-names></name>
<name><surname>Grootenboer-Mignot</surname><given-names>S.</given-names></name>
<name><surname>Palazzo</surname><given-names>E.</given-names></name>
<name><surname>Hayem</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus</article-title>. <source>Arthritis Res Ther</source> <volume>11</volume>(<issue>3</issue>): <fpage>R87</fpage>.</citation>
</ref>
<ref id="bibr112-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Min</surname><given-names>D.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Park</surname><given-names>S.</given-names></name>
<name><surname>Seo</surname><given-names>Y.</given-names></name>
<name><surname>Kang</surname><given-names>H.</given-names></name>
<name><surname>Kim</surname><given-names>W.</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Anti-nucleosome antibody: significance in lupus patients lacking anti-double-stranded DNA antibody</article-title>. <source>Clin Exp Rheumatol</source> <volume>20</volume>: <fpage>13</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr113-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mishra</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>Q.</given-names></name>
<name><surname>Prada</surname><given-names>A.</given-names></name>
<name><surname>Mitsnefes</surname><given-names>M.</given-names></name>
<name><surname>Zahedi</surname><given-names>K.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury</article-title>. <source>J Am Soc Nephrol</source> <volume>14</volume>: <fpage>2534</fpage>–<lpage>2543</lpage>.</citation>
</ref>
<ref id="bibr114-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mitoma</surname><given-names>H.</given-names></name>
<name><surname>Horiuchi</surname><given-names>T.</given-names></name>
<name><surname>Kimoto</surname><given-names>Y.</given-names></name>
<name><surname>Tsukamoto</surname><given-names>H.</given-names></name>
<name><surname>Uchino</surname><given-names>A.</given-names></name>
<name><surname>Tamimoto</surname><given-names>Y.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Decreased expression of interleukin-21 receptor on peripheral B lymphocytes in systemic lupus erythematosus</article-title>. <source>Int J Mol Med</source> <volume>16</volume>: <fpage>609</fpage>–<lpage>615</lpage>.</citation>
</ref>
<ref id="bibr115-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mohan</surname><given-names>C.</given-names></name>
<name><surname>Adams</surname><given-names>S.</given-names></name>
<name><surname>Stanik</surname><given-names>V.</given-names></name>
<name><surname>Datta</surname><given-names>S.</given-names></name>
</person-group> (<year>1993</year>) <article-title>Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus</article-title>. <source>J Exp Med</source> <volume>177</volume>: <fpage>1367</fpage>–<lpage>1381</lpage>.</citation>
</ref>
<ref id="bibr116-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mok</surname><given-names>C.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Biomarkers for lupus nephritis: a critical appraisal</article-title>. <source>J Biomed Biotechnol</source> <volume>2010</volume>: <fpage>638413</fpage>.</citation>
</ref>
<ref id="bibr117-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mok</surname><given-names>C.</given-names></name>
<name><surname>Lau</surname><given-names>C.</given-names></name>
</person-group> (<year>2003</year>) <article-title>Pathogenesis of systemic lupus erythematosus</article-title>. <source>J Clin Pathol</source> <volume>56</volume>(<issue>7</issue>): <fpage>481</fpage>–<lpage>490</lpage>.</citation>
</ref>
<ref id="bibr118-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moore</surname><given-names>P.</given-names></name>
<name><surname>Belvedere</surname><given-names>O.</given-names></name>
<name><surname>Orr</surname><given-names>A.</given-names></name>
<name><surname>Pieri</surname><given-names>K.</given-names></name>
<name><surname>LaFleur</surname><given-names>D.</given-names></name>
<name><surname>Feng</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator</article-title>. <source>Science</source> <volume>285</volume>: <fpage>260</fpage>–<lpage>263</lpage>.</citation>
</ref>
<ref id="bibr119-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moroni</surname><given-names>G.</given-names></name>
<name><surname>Radice</surname><given-names>A.</given-names></name>
<name><surname>Giammarresi</surname><given-names>G.</given-names></name>
<name><surname>Quaglini</surname><given-names>S.</given-names></name>
<name><surname>Gallelli</surname><given-names>B.</given-names></name>
<name><surname>Leoni</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis</article-title>. <source>Ann Rheum Dis</source> <volume>68</volume>: <fpage>234</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr120-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moroni</surname><given-names>G.</given-names></name>
<name><surname>Trendelenburg</surname><given-names>M.</given-names></name>
<name><surname>Papa</surname><given-names>N.</given-names></name>
<name><surname>Quaglini</surname><given-names>S.</given-names></name>
<name><surname>Raschi</surname><given-names>E.</given-names></name>
<name><surname>Panzeri</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis</article-title>. <source>Am J Kidney Dis</source> <volume>37</volume>: <fpage>490</fpage>–<lpage>498</lpage>.</citation>
</ref>
<ref id="bibr121-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moser</surname><given-names>K.</given-names></name>
<name><surname>Kelly</surname><given-names>J.</given-names></name>
<name><surname>Lessard</surname><given-names>C.</given-names></name>
<name><surname>Harley</surname><given-names>J.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Recent insights into the genetic basis of systemic lupus erythematosus</article-title>. <source>Genes Immun</source> <volume>10</volume>: <fpage>373</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr122-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mosley</surname><given-names>K.</given-names></name>
<name><surname>Tam</surname><given-names>F.</given-names></name>
<name><surname>Edwards</surname><given-names>R.</given-names></name>
<name><surname>Crozier</surname><given-names>J.</given-names></name>
<name><surname>Pusey</surname><given-names>C.</given-names></name>
<name><surname>Lightstone</surname><given-names>L.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Urinary proteomic profiles distinguish between active and inactive lupus nephritis</article-title>. <source>Rheumatology (Oxford)</source> <volume>45</volume>: <fpage>1497</fpage>–<lpage>1504</lpage>.</citation>
</ref>
<ref id="bibr123-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moulton</surname><given-names>V.</given-names></name>
<name><surname>Tsokos</surname><given-names>G.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Abnormalities of T cell signaling in systemic lupus erythematosus</article-title>. <source>Arthritis Res Ther</source> <volume>13</volume>: <fpage>207</fpage>.</citation>
</ref>
<ref id="bibr124-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nardelli</surname><given-names>B.</given-names></name>
<name><surname>Belvedere</surname><given-names>O.</given-names></name>
<name><surname>Roschke</surname><given-names>V.</given-names></name>
<name><surname>Moore</surname><given-names>P.</given-names></name>
<name><surname>Olsen</surname><given-names>H.</given-names></name>
<name><surname>Migone</surname><given-names>T.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Synthesis and release of B-lymphocyte stimulator from myeloid cells</article-title>. <source>Blood</source> <volume>97</volume>: <fpage>198</fpage>–<lpage>204</lpage>.</citation>
</ref>
<ref id="bibr125-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nath</surname><given-names>S.</given-names></name>
<name><surname>Kilpatrick</surname><given-names>J.</given-names></name>
<name><surname>Harley</surname><given-names>J.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Genetics of human systemic lupus erythematosus: the emerging picture</article-title>. <source>Curr Opin Immunol</source> <volume>16</volume>: <fpage>794</fpage>–<lpage>800</lpage>.</citation>
</ref>
<ref id="bibr126-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nikpour</surname><given-names>M.</given-names></name>
<name><surname>Dempsey</surname><given-names>A.</given-names></name>
<name><surname>Urowitz</surname><given-names>M.</given-names></name>
<name><surname>Gladman</surname><given-names>D.</given-names></name>
<name><surname>Barnes</surname><given-names>D.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Association of a gene expression profile from whole blood with disease activity in systemic lupus erythematosus</article-title>. <source>Ann Rheum Dis</source> <volume>67</volume>: <fpage>1069</fpage>–<lpage>1075</lpage>.</citation>
</ref>
<ref id="bibr127-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Noris</surname><given-names>M.</given-names></name>
<name><surname>Bernasconi</surname><given-names>S.</given-names></name>
<name><surname>Casiraghi</surname><given-names>F.</given-names></name>
<name><surname>Sozzani</surname><given-names>S.</given-names></name>
<name><surname>Gotti</surname><given-names>E.</given-names></name>
<name><surname>Remuzzi</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>1995</year>) <article-title>Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis</article-title>. <source>Lab Invest</source> <volume>73</volume>: <fpage>804</fpage>–<lpage>809</lpage>.</citation>
</ref>
<ref id="bibr128-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Brien</surname><given-names>R.</given-names></name>
<name><surname>Roark</surname><given-names>C.</given-names></name>
<name><surname>Born</surname><given-names>W</given-names></name>
</person-group>. (<year>2009</year>) <article-title>IL-17-producing gammadelta T cells</article-title>. <source>Eur J Immunol</source> <volume>39</volume>: <fpage>662</fpage>–<lpage>666</lpage>.</citation>
</ref>
<ref id="bibr129-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Obermoser</surname><given-names>G.</given-names></name>
<name><surname>Pascual</surname><given-names>V.</given-names></name>
</person-group> (<year>2010</year>) <article-title>The interferon-alpha signature of systemic lupus erythematosus</article-title>. <source>Lupus</source> <volume>19</volume>: <fpage>1012</fpage>–<lpage>1019</lpage>.</citation>
</ref>
<ref id="bibr130-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oelke</surname><given-names>K.</given-names></name>
<name><surname>Lu</surname><given-names>Q.</given-names></name>
<name><surname>Richardson</surname><given-names>D.</given-names></name>
<name><surname>Wu</surname><given-names>A.</given-names></name>
<name><surname>Deng</surname><given-names>C.</given-names></name>
<name><surname>Hanash</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors</article-title>. <source>Arthritis Rheum</source> <volume>50</volume>: <fpage>1850</fpage>–<lpage>1860</lpage>.</citation>
</ref>
<ref id="bibr131-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ouyang</surname><given-names>W.</given-names></name>
<name><surname>Kolls</surname><given-names>J.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
</person-group> (<year>2008</year>) <article-title>The biological functions of T helper 17 cell effector cytokines in inflammation</article-title>. <source>Immunity</source> <volume>28</volume>: <fpage>454</fpage>–<lpage>467</lpage>.</citation>
</ref>
<ref id="bibr132-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pan</surname><given-names>W.</given-names></name>
<name><surname>Zhu</surname><given-names>S.</given-names></name>
<name><surname>Yuan</surname><given-names>M.</given-names></name>
<name><surname>Cui</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Luo</surname><given-names>X.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1</article-title>. <source>J Immunol</source> <volume>184</volume>: <fpage>6773</fpage>–<lpage>6781</lpage>.</citation>
</ref>
<ref id="bibr133-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pers</surname><given-names>J.</given-names></name>
<name><surname>Daridon</surname><given-names>C.</given-names></name>
<name><surname>Devauchelle</surname><given-names>V.</given-names></name>
<name><surname>Jousse</surname><given-names>S.</given-names></name>
<name><surname>Saraux</surname><given-names>A.</given-names></name>
<name><surname>Jamin</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>BAFF overexpression is associated with autoantibody production in autoimmune diseases</article-title>. <source>Ann N Y Acad Sci</source> <volume>1050</volume>: <fpage>34</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr134-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Petri</surname><given-names>M.</given-names></name>
<name><surname>Singh</surname><given-names>S.</given-names></name>
<name><surname>Tesfasyone</surname><given-names>H.</given-names></name>
<name><surname>Dedrick</surname><given-names>R.</given-names></name>
<name><surname>Fry</surname><given-names>K.</given-names></name>
<name><surname>Lal</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus</article-title>. <source>Lupus</source> <volume>18</volume>: <fpage>980</fpage>–<lpage>989</lpage>.</citation>
</ref>
<ref id="bibr135-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Petri</surname><given-names>M.</given-names></name>
<name><surname>Stohl</surname><given-names>W.</given-names></name>
<name><surname>Chatham</surname><given-names>W.</given-names></name>
<name><surname>McCune</surname><given-names>W.</given-names></name>
<name><surname>Chevrier</surname><given-names>M.</given-names></name>
<name><surname>Ryel</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <volume>58</volume>: <fpage>2453</fpage>–<lpage>2459</lpage>.</citation>
</ref>
<ref id="bibr136-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pickering</surname><given-names>M.</given-names></name>
<name><surname>Botto</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Are anti-C1q antibodies different from other SLE autoantibodies?</article-title> <source>Nat Rev Rheumatol</source> <volume>6</volume>: <fpage>490</fpage>–<lpage>493</lpage>.</citation>
</ref>
<ref id="bibr137-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pickering</surname><given-names>M.</given-names></name>
<name><surname>Botto</surname><given-names>M.</given-names></name>
<name><surname>Taylor</surname><given-names>P.</given-names></name>
<name><surname>Lachmann</surname><given-names>P.</given-names></name>
<name><surname>Walport</surname><given-names>M.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Systemic lupus erythematosus, complement deficiency, and apoptosis</article-title>. <source>Adv Immunol</source> <volume>76</volume>: <fpage>227</fpage>–<lpage>324</lpage>.</citation>
</ref>
<ref id="bibr138-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pitashny</surname><given-names>M.</given-names></name>
<name><surname>Schwartz</surname><given-names>N.</given-names></name>
<name><surname>Qing</surname><given-names>X.</given-names></name>
<name><surname>Hojaili</surname><given-names>B.</given-names></name>
<name><surname>Aranow</surname><given-names>C.</given-names></name>
<name><surname>Mackay</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis</article-title>. <source>Arthritis Rheum</source> <volume>56</volume>: <fpage>1894</fpage>–<lpage>1903</lpage>.</citation>
</ref>
<ref id="bibr139-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Potlukova</surname><given-names>E.</given-names></name>
<name><surname>Kralikova</surname><given-names>P.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Complement component c1q and anti-c1q antibodies in theory and in clinical practice</article-title>. <source>Scand J Immunol</source> <volume>67</volume>: <fpage>423</fpage>–<lpage>430</lpage>.</citation>
</ref>
<ref id="bibr140-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rahman</surname><given-names>A.</given-names></name>
<name><surname>Isenberg</surname><given-names>D.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Systemic lupus erythematosus</article-title>. <source>N Engl J Med</source> <volume>358</volume>: <fpage>929</fpage>–<lpage>939</lpage>.</citation>
</ref>
<ref id="bibr141-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rauch</surname><given-names>T.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Zhong</surname><given-names>X.</given-names></name>
<name><surname>Riggs</surname><given-names>A.</given-names></name>
<name><surname>Pfeifer</surname><given-names>G.</given-names></name>
</person-group> (<year>2009</year>) <article-title>A human B cell methylome at 100-base pair resolution</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>106</volume>: <fpage>671</fpage>–<lpage>678</lpage>.</citation>
</ref>
<ref id="bibr142-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Renaudineau</surname><given-names>Y.</given-names></name>
<name><surname>Youinou</surname><given-names>P.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Epigenetics and autoimmunity, with special emphasis on methylation</article-title>. <source>Keio J Med</source> <volume>60</volume>: <fpage>10</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr143-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Richardson</surname><given-names>B.</given-names></name>
<name><surname>Scheinbart</surname><given-names>L.</given-names></name>
<name><surname>Strahler</surname><given-names>J.</given-names></name>
<name><surname>Gross</surname><given-names>L.</given-names></name>
<name><surname>Hanash</surname><given-names>S.</given-names></name>
<name><surname>Johnson</surname><given-names>M.</given-names></name>
</person-group> (<year>1990</year>) <article-title>Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source> <volume>33</volume>: <fpage>1665</fpage>–<lpage>1673</lpage>.</citation>
</ref>
<ref id="bibr144-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ritterhouse</surname><given-names>L.</given-names></name>
<name><surname>Crowe</surname><given-names>S.</given-names></name>
<name><surname>Niewold</surname><given-names>T.</given-names></name>
<name><surname>Merrill</surname><given-names>J.</given-names></name>
<name><surname>Roberts</surname><given-names>V.</given-names></name>
<name><surname>Dedeke</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels</article-title>. <source>Arthritis Rheum</source> <volume>63</volume>: <fpage>3931</fpage>–<lpage>3941</lpage>.</citation>
</ref>
<ref id="bibr145-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roh</surname><given-names>T.</given-names></name>
<name><surname>Cuddapah</surname><given-names>S.</given-names></name>
<name><surname>Zhao</surname><given-names>K.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Active chromatin domains are defined by acetylation islands revealed by genome-wide mapping</article-title>. <source>Genes Dev</source> <volume>19</volume>: <fpage>542</fpage>–<lpage>552</lpage>.</citation>
</ref>
<ref id="bibr146-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rose</surname><given-names>T.</given-names></name>
<name><surname>Grutzkau</surname><given-names>A.</given-names></name>
<name><surname>Hirseland</surname><given-names>H.</given-names></name>
<name><surname>Huscher</surname><given-names>D.</given-names></name>
<name><surname>Dahnrich</surname><given-names>C.</given-names></name>
<name><surname>Dzionek</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus</article-title>. <source>Ann Rheum Dis</source>, in press.</citation>
</ref>
<ref id="bibr147-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rovin</surname><given-names>B.</given-names></name>
<name><surname>Doe</surname><given-names>N.</given-names></name>
<name><surname>Tan</surname><given-names>L.</given-names></name>
</person-group> (<year>1996</year>) <article-title>Monocyte chemoattractant protein-1 levels in patients with glomerular disease</article-title>. <source>Am J Kidney Dis</source> <volume>27</volume>: <fpage>640</fpage>–<lpage>646</lpage>.</citation>
</ref>
<ref id="bibr148-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rovin</surname><given-names>B.</given-names></name>
<name><surname>Song</surname><given-names>H.</given-names></name>
<name><surname>Birmingham</surname><given-names>D.</given-names></name>
<name><surname>Hebert</surname><given-names>L.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
<name><surname>Nagaraja</surname><given-names>H.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Urine chemokines as biomarkers of human systemic lupus erythematosus activity</article-title>. <source>J Am Soc Nephrol</source> <volume>16</volume>: <fpage>467</fpage>–<lpage>473</lpage>.</citation>
</ref>
<ref id="bibr149-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rovin</surname><given-names>B.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Biomarkers for lupus nephritis: the quest continues</article-title>. <source>Clin J Am Soc Nephrol</source> <volume>4</volume>: <fpage>1858</fpage>–<lpage>1865</lpage>.</citation>
</ref>
<ref id="bibr150-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rubinstein</surname><given-names>T.</given-names></name>
<name><surname>Pitashny</surname><given-names>M.</given-names></name>
<name><surname>Levine</surname><given-names>B.</given-names></name>
<name><surname>Schwartz</surname><given-names>N.</given-names></name>
<name><surname>Schwartzman</surname><given-names>J.</given-names></name>
<name><surname>Weinstein</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis</article-title>. <source>Rheumatology (Oxford)</source> <volume>49</volume>: <fpage>960</fpage>–<lpage>971</lpage>.</citation>
</ref>
<ref id="bibr151-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Santer</surname><given-names>D.</given-names></name>
<name><surname>Yoshio</surname><given-names>T.</given-names></name>
<name><surname>Minota</surname><given-names>S.</given-names></name>
<name><surname>Moller</surname><given-names>T.</given-names></name>
<name><surname>Elkon</surname><given-names>K.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus</article-title>. <source>J Immunol</source> <volume>182</volume>: <fpage>1192</fpage>–<lpage>1201</lpage>.</citation>
</ref>
<ref id="bibr152-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanz</surname><given-names>A.</given-names></name>
<name><surname>Justo</surname><given-names>P.</given-names></name>
<name><surname>Sanchez-Nino</surname><given-names>M.</given-names></name>
<name><surname>Blanco-Colio</surname><given-names>L.</given-names></name>
<name><surname>Winkles</surname><given-names>J.</given-names></name>
<name><surname>Kreztler</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>The cytokine TWEAK modulates renal tubulointerstitial inflammation</article-title>. <source>J Am Soc Nephrol</source> <volume>19</volume>: <fpage>695</fpage>–<lpage>703</lpage>.</citation>
</ref>
<ref id="bibr153-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sarzi-Puttini</surname><given-names>P.</given-names></name>
<name><surname>Atzeni</surname><given-names>F.</given-names></name>
<name><surname>Iaccarino</surname><given-names>L.</given-names></name>
<name><surname>Doria</surname><given-names>A.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Environment and systemic lupus erythematosus: an overview</article-title>. <source>Autoimmunity</source> <volume>38</volume>: <fpage>465</fpage>–<lpage>472</lpage>.</citation>
</ref>
<ref id="bibr154-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schwartz</surname><given-names>N.</given-names></name>
<name><surname>Michaelson</surname><given-names>J.</given-names></name>
<name><surname>Putterman</surname><given-names>C.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis</article-title>. <source>Ann N Y Acad Sci</source> <volume>1109</volume>: <fpage>265</fpage>–<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr155-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schwartz</surname><given-names>N.</given-names></name>
<name><surname>Rubinstein</surname><given-names>T.</given-names></name>
<name><surname>Burkly</surname><given-names>L.</given-names></name>
<name><surname>Collins</surname><given-names>C.</given-names></name>
<name><surname>Blanco</surname><given-names>I.</given-names></name>
<name><surname>Su</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study</article-title>. <source>Arthritis Res Ther</source> <volume>11</volume>(<issue>5</issue>): <fpage>R143</fpage>.</citation>
</ref>
<ref id="bibr156-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schwartz</surname><given-names>N.</given-names></name>
<name><surname>Su</surname><given-names>L.</given-names></name>
<name><surname>Burkly</surname><given-names>L.</given-names></name>
<name><surname>Mackay</surname><given-names>M.</given-names></name>
<name><surname>Aranow</surname><given-names>C.</given-names></name>
<name><surname>Kollaros</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Urinary TWEAK and the activity of lupus nephritis</article-title>. <source>J Autoimmun</source> <volume>27</volume>: <fpage>242</fpage>–<lpage>250</lpage>.</citation>
</ref>
<ref id="bibr157-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shah</surname><given-names>K.</given-names></name>
<name><surname>Lee</surname><given-names>W.</given-names></name>
<name><surname>Lee</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Kang</surname><given-names>S.</given-names></name>
<name><surname>Craft</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus</article-title>. <source>Arthritis Res Ther</source> <volume>12</volume>(<issue>2</issue>): <fpage>R53</fpage>.</citation>
</ref>
<ref id="bibr158-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shen</surname><given-names>N.</given-names></name>
<name><surname>Liang</surname><given-names>D.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
<name><surname>de Vries</surname><given-names>N.</given-names></name>
<name><surname>Tak</surname><given-names>P.</given-names></name>
</person-group> (<year>2012</year>) <article-title>MicroRNAs-novel regulators of systemic lupus erythematosus pathogenesis</article-title>. <source>Nat Rev Rheumatol</source> <volume>8</volume>: <fpage>701</fpage>–<lpage>709</lpage>.</citation>
</ref>
<ref id="bibr159-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sinico</surname><given-names>R.</given-names></name>
<name><surname>Rimoldi</surname><given-names>L.</given-names></name>
<name><surname>Radice</surname><given-names>A.</given-names></name>
<name><surname>Bianchi</surname><given-names>L.</given-names></name>
<name><surname>Gallelli</surname><given-names>B.</given-names></name>
<name><surname>Moroni</surname><given-names>G.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Anti-C1q autoantibodies in lupus nephritis</article-title>. <source>Ann N Y Acad Sci</source> <volume>1173</volume>: <fpage>47</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr160-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Snowden</surname><given-names>A.</given-names></name>
<name><surname>Gregory</surname><given-names>P.</given-names></name>
<name><surname>Case</surname><given-names>C.</given-names></name>
<name><surname>Pabo</surname><given-names>C.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo</article-title>. <source>Curr Biol</source> <volume>12</volume>: <fpage>2159</fpage>–<lpage>2166</lpage>.</citation>
</ref>
<ref id="bibr161-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stagakis</surname><given-names>E.</given-names></name>
<name><surname>Bertsias</surname><given-names>G.</given-names></name>
<name><surname>Verginis</surname><given-names>P.</given-names></name>
<name><surname>Nakou</surname><given-names>M.</given-names></name>
<name><surname>Hatziapostolou</surname><given-names>M.</given-names></name>
<name><surname>Kritikos</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression</article-title>. <source>Ann Rheum Dis</source> <volume>70</volume>: <fpage>1496</fpage>–<lpage>1506</lpage>.</citation>
</ref>
<ref id="bibr162-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stohl</surname><given-names>W.</given-names></name>
<name><surname>Metyas</surname><given-names>S.</given-names></name>
<name><surname>Tan</surname><given-names>S.</given-names></name>
<name><surname>Cheema</surname><given-names>G.</given-names></name>
<name><surname>Oamar</surname><given-names>B.</given-names></name>
<name><surname>Xu</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations</article-title>. <source>Arthritis Rheum</source> <volume>48</volume>: <fpage>3475</fpage>–<lpage>3486</lpage>.</citation>
</ref>
<ref id="bibr163-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suzuki</surname><given-names>M.</given-names></name>
<name><surname>Ross</surname><given-names>G.</given-names></name>
<name><surname>Wiers</surname><given-names>K.</given-names></name>
<name><surname>Nelson</surname><given-names>S.</given-names></name>
<name><surname>Bennett</surname><given-names>M.</given-names></name>
<name><surname>Passo</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Identification of a urinary proteomic signature for lupus nephritis in children</article-title>. <source>Pediatr Nephrol</source> <volume>22</volume>: <fpage>2047</fpage>–<lpage>2057</lpage>.</citation>
</ref>
<ref id="bibr164-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suzuki</surname><given-names>M.</given-names></name>
<name><surname>Wiers</surname><given-names>K.</given-names></name>
<name><surname>Brooks</surname><given-names>E.</given-names></name>
<name><surname>Greis</surname><given-names>K.</given-names></name>
<name><surname>Haines</surname><given-names>K.</given-names></name>
<name><surname>Klein-Gitelman</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis</article-title>. <source>Pediatr Res</source> <volume>65</volume>: <fpage>530</fpage>–<lpage>536</lpage>.</citation>
</ref>
<ref id="bibr165-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suzuki</surname><given-names>M.</given-names></name>
<name><surname>Wiers</surname><given-names>K.</given-names></name>
<name><surname>Klein-Gitelman</surname><given-names>M.</given-names></name>
<name><surname>Haines</surname><given-names>K.</given-names></name>
<name><surname>Olson</surname><given-names>J.</given-names></name>
<name><surname>Onel</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis</article-title>. <source>Pediatr Nephrol</source> <volume>23</volume>: <fpage>403</fpage>–<lpage>412</lpage>.</citation>
</ref>
<ref id="bibr166-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tang</surname><given-names>Y.</given-names></name>
<name><surname>Luo</surname><given-names>X.</given-names></name>
<name><surname>Cui</surname><given-names>H.</given-names></name>
<name><surname>Ni</surname><given-names>X.</given-names></name>
<name><surname>Yuan</surname><given-names>M.</given-names></name>
<name><surname>Guo</surname><given-names>Y.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins</article-title>. <source>Arthritis Rheum</source> <volume>60</volume>: <fpage>1065</fpage>–<lpage>1075</lpage>.</citation>
</ref>
<ref id="bibr167-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Te</surname><given-names>J.</given-names></name>
<name><surname>Dozmorov</surname><given-names>I.</given-names></name>
<name><surname>Guthridge</surname><given-names>J.</given-names></name>
<name><surname>Nguyen</surname><given-names>K.</given-names></name>
<name><surname>Cavett</surname><given-names>J.</given-names></name>
<name><surname>Kelly</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Identification of unique microRNA signature associated with lupus nephritis</article-title>. <source>PLoS One</source> <volume>5</volume>(<issue>5</issue>): <fpage>e10344</fpage>.</citation>
</ref>
<ref id="bibr168-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tian</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>T.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Cheng</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare</article-title>. <source>Inflamm Res</source> <volume>56</volume>: <fpage>304</fpage>–<lpage>310</lpage>.</citation>
</ref>
<ref id="bibr169-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trachtman</surname><given-names>H.</given-names></name>
<name><surname>Christen</surname><given-names>E.</given-names></name>
<name><surname>Cnaan</surname><given-names>A.</given-names></name>
<name><surname>Patrick</surname><given-names>J.</given-names></name>
<name><surname>Mai</surname><given-names>V.</given-names></name>
<name><surname>Mishra</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury</article-title>. <source>Pediatr Nephrol</source> <volume>21</volume>: <fpage>989</fpage>–<lpage>994</lpage>.</citation>
</ref>
<ref id="bibr170-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trendelenburg</surname><given-names>M.</given-names></name>
<name><surname>Lopez-Trascasa</surname><given-names>M.</given-names></name>
<name><surname>Potlukova</surname><given-names>E.</given-names></name>
<name><surname>Moll</surname><given-names>S.</given-names></name>
<name><surname>Regenass</surname><given-names>S.</given-names></name>
<name><surname>Fremeaux-Bacchi</surname><given-names>V.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis</article-title>. <source>Nephrol Dialysis Transplant</source> <volume>21</volume>: <fpage>3115</fpage>–<lpage>3121</lpage>.</citation>
</ref>
<ref id="bibr171-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trendelenburg</surname><given-names>M.</given-names></name>
<name><surname>Marfurt</surname><given-names>J.</given-names></name>
<name><surname>Gerber</surname><given-names>I.</given-names></name>
<name><surname>Tyndall</surname><given-names>A.</given-names></name>
<name><surname>Schifferli</surname><given-names>J.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients</article-title>. <source>Arthritis Rheum</source> <volume>42</volume>: <fpage>187</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr172-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsokos</surname><given-names>G.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Systemic lupus erythematosus</article-title>. <source>N Engl J Med</source> <volume>365</volume>: <fpage>2110</fpage>–<lpage>2121</lpage>.</citation>
</ref>
<ref id="bibr173-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tucci</surname><given-names>M.</given-names></name>
<name><surname>Barnes</surname><given-names>E.</given-names></name>
<name><surname>Sobel</surname><given-names>E.</given-names></name>
<name><surname>Croker</surname><given-names>B.</given-names></name>
<name><surname>Segal</surname><given-names>M.</given-names></name>
<name><surname>Reeves</surname><given-names>W.</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis</article-title>. <source>Arthritis Rheum</source> <volume>50</volume>: <fpage>1842</fpage>–<lpage>1849</lpage>.</citation>
</ref>
<ref id="bibr174-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vila</surname><given-names>L.</given-names></name>
<name><surname>Molina</surname><given-names>M.</given-names></name>
<name><surname>Mayor</surname><given-names>A.</given-names></name>
<name><surname>Cruz</surname><given-names>J.</given-names></name>
<name><surname>Rios-Olivares</surname><given-names>E.</given-names></name>
<name><surname>Rios</surname><given-names>Z.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Association of serum MIP-1alpha, MIP-1beta, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus</article-title>. <source>Clin Rheumatol</source> <volume>26</volume>: <fpage>718</fpage>–<lpage>722</lpage>.</citation>
</ref>
<ref id="bibr175-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wada</surname><given-names>T.</given-names></name>
<name><surname>Yokoyama</surname><given-names>H.</given-names></name>
<name><surname>Su</surname><given-names>S.</given-names></name>
<name><surname>Mukaida</surname><given-names>N.</given-names></name>
<name><surname>Iwano</surname><given-names>M.</given-names></name>
<name><surname>Dohi</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>1996</year>) <article-title>Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis</article-title>. <source>Kidney Int</source> <volume>49</volume>: <fpage>761</fpage>–<lpage>767</lpage>.</citation>
</ref>
<ref id="bibr176-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>G.</given-names></name>
<name><surname>Tam</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>E.</given-names></name>
<name><surname>Kwan</surname><given-names>B.</given-names></name>
<name><surname>Chow</surname><given-names>K.</given-names></name>
<name><surname>Luk</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <volume>37</volume>: <fpage>2516</fpage>–<lpage>2522</lpage>.</citation>
</ref>
<ref id="bibr177-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Peng</surname><given-names>W.</given-names></name>
<name><surname>Ouyang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Dai</surname><given-names>Y.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus</article-title>. <source>Transl Res</source> <volume>160</volume>: <fpage>198</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr178-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Watson</surname><given-names>L.</given-names></name>
<name><surname>Beresford</surname><given-names>M.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Urine biomarkers in juvenile-onset SLE nephritis</article-title>. <source>Pediatr Nephrol</source>, in press.</citation>
</ref>
<ref id="bibr179-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Watson</surname><given-names>L.</given-names></name>
<name><surname>Midgley</surname><given-names>A.</given-names></name>
<name><surname>Pilkington</surname><given-names>C.</given-names></name>
<name><surname>Tullus</surname><given-names>K.</given-names></name>
<name><surname>Marks</surname><given-names>S.</given-names></name>
<name><surname>Holt</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Urinary monocyte chemoattractant protein 1 and alpha 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus</article-title>. <source>Lupus</source> <volume>21</volume>: <fpage>496</fpage>–<lpage>501</lpage>.</citation>
</ref>
<ref id="bibr180-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weckerle</surname><given-names>C.</given-names></name>
<name><surname>Niewold</surname><given-names>T.</given-names></name>
</person-group> (<year>2011</year>) <article-title>The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies</article-title>. <source>Clin Rev Allergy Immunol</source> <volume>40</volume>: <fpage>42</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr181-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Williamson</surname><given-names>W.</given-names></name>
<name><surname>Pinto</surname><given-names>I.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Histones and genome integrity</article-title>. <source>Front Biosci</source> <volume>17</volume>: <fpage>984</fpage>–<lpage>995</lpage>.</citation>
</ref>
<ref id="bibr182-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>C.</given-names></name>
<name><surname>Rowell</surname><given-names>E.</given-names></name>
<name><surname>Sekimata</surname><given-names>M.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Epigenetic control of T-helper-cell differentiation</article-title>. <source>Nat Rev Immunol</source> <volume>9</volume>: <fpage>91</fpage>–<lpage>105</lpage>.</citation>
</ref>
<ref id="bibr183-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winfield</surname><given-names>J.</given-names></name>
<name><surname>Shaw</surname><given-names>M.</given-names></name>
<name><surname>Silverman</surname><given-names>L.</given-names></name>
<name><surname>Eisenberg</surname><given-names>R.</given-names></name>
<name><surname>Wilson</surname><given-names>H.</given-names><suffix>III</suffix></name>
<name><surname>Koffler</surname><given-names>D.</given-names></name>
</person-group> (<year>1983</year>) <article-title>Intrathecal IgG synthesis and blood–brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction</article-title>. <source>Am J Med</source> <volume>74</volume>: <fpage>837</fpage>–<lpage>844</lpage>.</citation>
</ref>
<ref id="bibr184-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winkles</surname><given-names>J.</given-names></name>
</person-group> (<year>2008</year>) <article-title>The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting</article-title>. <source>Nat Rev Drug Discov</source> <volume>7</volume>: <fpage>411</fpage>–<lpage>425</lpage>.</citation>
</ref>
<ref id="bibr185-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wong</surname><given-names>C.</given-names></name>
<name><surname>Ho</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>E.</given-names></name>
<name><surname>Lam</surname><given-names>C.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus</article-title>. <source>Lupus</source> <volume>9</volume>: <fpage>589</fpage>–<lpage>593</lpage>.</citation>
</ref>
<ref id="bibr186-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>C.</given-names></name>
<name><surname>Rajewsky</surname><given-names>K.</given-names></name>
</person-group> (<year>2009</year>) <article-title>MicroRNA control in the immune system: basic principles</article-title>. <source>Cell</source> <volume>136</volume>: <fpage>26</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr187-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>C.</given-names></name>
<name><surname>Hsieh</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Wu</surname><given-names>C.</given-names></name>
<name><surname>Lu</surname><given-names>M.</given-names></name>
<name><surname>Tsai</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Urinary neutrophil gelatinase-associated lipocalin is a potential biomarker for renal damage in patients with systemic lupus erythematosus</article-title>. <source>J Biomed Biotechnol</source> <volume>2012</volume>: <fpage>759313</fpage>.</citation>
</ref>
<ref id="bibr188-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Chu</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Gao</surname><given-names>D.</given-names></name>
<name><surname>Zhu</surname><given-names>L.</given-names></name>
<name><surname>Wan</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Th17 and natural Treg cell population dynamics in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <volume>60</volume>: <fpage>1472</fpage>–<lpage>1483</lpage>.</citation>
</ref>
<ref id="bibr189-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yao</surname><given-names>Y.</given-names></name>
<name><surname>Higgs</surname><given-names>B.W.</given-names></name>
<name><surname>Richman</surname><given-names>L.</given-names></name>
<name><surname>White</surname><given-names>B.</given-names></name>
<name><surname>Jallal</surname><given-names>B.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNalpha antibody, in systemic lupus erythematosus</article-title>. <source>Arthritis Res Ther</source> <volume>12</volume>(<supplement>Suppl. 1</supplement>): <fpage>S6</fpage>.</citation>
</ref>
<ref id="bibr190-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ytterberg</surname><given-names>S.</given-names></name>
<name><surname>Schnitzer</surname><given-names>T.</given-names></name>
</person-group> (<year>1982</year>) <article-title>Serum interferon levels in patients with systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <volume>25</volume>: <fpage>401</fpage>–<lpage>406</lpage>.</citation>
</ref>
<ref id="bibr191-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yu</surname><given-names>B.</given-names></name>
<name><surname>Shao</surname><given-names>Y.</given-names></name>
<name><surname>Yue</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Guan</surname><given-names>M.</given-names></name>
<name><surname>Wan</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Copy number variations of Interleukin-12B and T-bet are associated with systemic lupus erythematosus</article-title>. <source>Rheumatology (Oxford)</source> <volume>50</volume>: <fpage>1201</fpage>–<lpage>1205</lpage>.</citation>
</ref>
<ref id="bibr192-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Roschke</surname><given-names>V.</given-names></name>
<name><surname>Baker</surname><given-names>K.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Alarcon</surname><given-names>G.</given-names></name>
<name><surname>Fessler</surname><given-names>B.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus</article-title>. <source>J Immunol</source> <volume>166</volume>: <fpage>6</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr193-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Nagaraja</surname><given-names>H.</given-names></name>
<name><surname>Nadasdy</surname><given-names>T.</given-names></name>
<name><surname>Song</surname><given-names>H.</given-names></name>
<name><surname>McKinley</surname><given-names>A.</given-names></name>
<name><surname>Prosek</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies</article-title>. <source>Kidney Int</source> <volume>81</volume>: <fpage>401</fpage>–<lpage>406</lpage>.</citation>
</ref>
<ref id="bibr194-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Kyttaris</surname><given-names>V.</given-names></name>
<name><surname>Tsokos</surname><given-names>G.</given-names></name>
</person-group> (<year>2009</year>) <article-title>The role of IL-23/IL-17 axis in lupus nephritis</article-title>. <source>J Immunol</source> <volume>183</volume>: <fpage>3160</fpage>–<lpage>3169</lpage>.</citation>
</ref>
<ref id="bibr195-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Song</surname><given-names>L.</given-names></name>
<name><surname>Maurer</surname><given-names>K.</given-names></name>
<name><surname>Petri</surname><given-names>M.</given-names></name>
<name><surname>Sullivan</surname><given-names>K.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes</article-title>. <source>Genes Immun</source> <volume>11</volume>: <fpage>124</fpage>–<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr196-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>M.</given-names></name>
<name><surname>Tang</surname><given-names>J.</given-names></name>
<name><surname>Gao</surname><given-names>F.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Liang</surname><given-names>Y.</given-names></name>
<name><surname>Yin</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>2010a</year>) <article-title>Hypomethylation of IL10 and IL13 promoters in CD4+ T cells of patients with systemic lupus erythematosus</article-title>. <source>J Biomed Biotechnol</source> <volume>2010</volume>: <fpage>931018</fpage>.</citation>
</ref>
<ref id="bibr197-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Liang</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>M.</given-names></name>
<name><surname>Long</surname><given-names>H.</given-names></name>
<name><surname>Ding</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1</article-title>. <source>Arthritis Rheum</source> <volume>63</volume>: <fpage>1376</fpage>–<lpage>1386</lpage>.</citation>
</ref>
<ref id="bibr198-1759720X13485503">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
<name><surname>Qu</surname><given-names>B.</given-names></name>
<name><surname>Cui</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2010b</year>) <article-title>MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <volume>62</volume>: <fpage>3425</fpage>–<lpage>3435</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>